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Summary 
SUMMARY  
 
 
The major mission of the cell division is a faithful and complete duplication of the genome 
with equal partition of chromosomes into subsequent cell generations. Progression through 
different stages of the cell cycle is governed by the activity of several members of the 
Cyclin-dependent kinase family, each pairing with the separate class of Cyclin. In higher 
eukaryotes, transition from G2 to M phase and completion of mitosis requires action of 
Cyclin B paired with Cdk1. Cdk1 is tightly regulated by 
phosphorylation/dephosphorylation processes and only full activation of Cyclin B/Cdk1 
complex triggers the initiation of mitosis. Although the role of Cdk1 is crucial and Cdk1 
remains the major regulator of mitosis, recent studies have broadened our knowledge of 
cell division, revealing the presence and importance of other protein kinases. Centrosome 
maturation and chromosome segregation requires the action of Polo-like kinases, whereas 
separation of centrosomes seems to be regulated by the kinase Nek2. An important role in 
centrosome separation, chromosome bi-orientation and cytokinesis has been postulated for 
Aurora family members.  
Genomic stability is under constant threat not only from the products of normal cellular 
metabolism, but also from radiation and chemicals present in the environment. To ensure 
proper cell division upon the occurrence damage to DNA, checkpoints are triggered and 
result in slowing or stopping cell cycle transitions. This, in turn, enables the repair of 
damage or, when it is too extensive, facilitate the triggering of cell death. Normal cells 
posses a full complement of cell cycle checkpoints, whereas cancer cells, in most cases, 
acquire mutations that result in bypass of the checkpoints. Nonetheless, the G2 checkpoint 
is operative also in cancer cells, since division with incompletely duplicated or damaged 
DNA is incompatible with life. At the molecular level the G2 checkpoint prevents cells 
from entering mitosis through inactivation of Cyclin B/Cdk1. This occurs in an 
ATM/ATR-dependent manner and involves Chk1/Chk2-mediated sub-cellular 
sequestration and inhibition or degradation of members of the Cdc25 family of 
phosphatases, which normally activate Cdk1 at the G2/M boundary. It has been recently 
discovered that kinases involved in spindle formation, like Plk1, Nek2 and Aurora B, play 
important roles in the cellular response to DNA damage. 
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In the studies presented in this dissertation I used etoposide, a topoisomerase II poison, to 
create double strand breaks in DNA, in order to elucidate the role of Aurora A in the DNA 
damage response. I found that Aurora A indeed is one of the targets of the double-strand 
break response in G2/M phase (Krystyniak A. et al, 2006). The kinase activity of the 
enzyme was actively inhibited upon etoposide treatment and this was accompanied by 
prolonged accumulation of the protein. I also addressed the issue of dependence between 
Aurora A and Cdk1, showing that the former is not downstream of the latter, but rather 
inhibition of Aurora A and Cdk1 by DNA damage occurs independently. By using 
caffeine, an ATM/ATR inhibitor, I showed that Aurora A de-activation in response to 
DNA damage was dependent on those kinases. More precisely, using cell lines deficient in 
ATM or conditionally expressing kinase-dead ATR, I was able to confirm that signalling to 
Aurora A was mediated through ATM. Further, by means of specifically blocking Chk1 
with its inhibitor UCN01 or by using siRNA to Chk1, I showed that the signals were 
delivered to Aurora A via a Chk1-dependent pathway. Those results were additionally 
confirmed by experiments with cells functionally deficient in Chk2 (HCT15). Looking for 
the mechanism responsible for Aurora A inhibition, I found that the point mutation S342 to 
A resulted in a mutant that was active and could not be inhibited by DNA damage. S342 
was already postulated as a negative site and it is located directly next to one of the binding 
motifs for PP1 – a known Aurora A interaction partner. Upon etoposide treatment, 
however, the interaction between Aurora A and PP1 is highly diminished (Krystyniak A. et 
al, manuscript submitted). Using the point mutant A342 of Aurora A I found that mutation 
to non-phosphorylable alanine prevents releasing of the phosphatase from the complex. On 
the contrary, mutation of the same site to aspartic acid, to mimick constitutive 
phosphorylation, resulted in complete abolishment of binding, irrespective of the presence 
of DNA damage.  
Finally, I took advantage of two independent approaches to examine the possibility that 
reconstitution of Aurora A activity in DNA damaged cells may trigger mitotic cell 
division. Transient transfection of cells with active (wild-type or S342A) but not with 
inactive (kinase-dead or S342D) forms of Aurora A, enabled them to bypass the DNA 
damage-induced cell cycle arrest and proceed to mitosis. To avoid large overexpression of 
proteins in transfection assays and given that such method requires time for the protein to 
be expressed, I used a more appropriate approach. This allows rapid transduction of 
proteins in the cell in a manner compatible with the kinetic of the G2 arrest in response to 
DNA damage. To this end, I directly transduced active AuroraA isoforms into G2-arrested 
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cells, immediately after inducing double-strand breaks in DNA. This resulted in mitotic 
entry, despite the unrepaired damage. A closer look to the molecular mechanism 
underlying progression to mitosis in these conditions revealed that active Aurora A 
promoted reactivation of Cdk1, thus indicating that Aurora A plays a key role upstream of 
Cdk1, at least under DNA damage conditions.  
Aurora A, similarly to other members of the family, is known to be regulated by 
phosphorylation. Phosphorylation of a conserved residue, T288, localized in the activation 
loop of the catalytic domain of the kinase, results in significant increase of Aurora A 
kinase activity. I was able to show that phosphorylation of T288 may occur through an 
intermolecular autophosphorylation mechanism. Moreover, I found that PKA, previously 
claimed to be the kinase responsible for this event in vitro, was not involved in T288 
phosphorylation in vivo. Surprisingly phosphorylation of this site, which is a direct 
indicator of the activity of the kinase, was found also in DNA-damaged cells to an extent 
comparable, or even higher than in mitotic cells. This situation is reminding of Cdk1, 
where phosphorylation at the T-loop residue T161 is hierarchically less important than 
inhibitory phosphorylation at the ATP-binding site. This finding points to presence of 
other, maybe structural, mechanisms responsible for the activity of Aurora A that remain to 
be discovered. 
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Zusammenfassung 
ZUSAMMENFASSUNG 
 
 
Die Hauptaufgabe der Zellteilung ist die korrekte und komplette Verdoppelung des 
Genoms und die folgende gleichmässige Aufteilung der Chromosomen auf die beiden 
Tochterzellen. Dieser Prozess wird durch eine Familie von Cyclin-abhängigen Kinasen 
dirigiert. Jede Kinase verbindet sich mit einer eigenen Klasse von Cyclinen, welche 
benötigt werden, um die verschiedenen Stadien des Zellzyklus zu durchlaufen. In höheren 
Eukaryoten sind der Übergang von der G2- zur M-Phase und der Abschluss der Mitose 
abhängig von der Aktivität eines Komplexes aus Cylin B und Cdk1. Die Aktivität von 
Cdk1 ist sehr straff reguliert durch Phoshorylierung und Dephosphorylierung. Die volle 
Aktivierung von Cyclin B/Cdk1 leitet die Mitose ein. Aktuelle Studien haben das Wissen 
über die Zellteilung erweitert und aufgezeigt, dass neben Cdk1 auch weitere 
Proteinkinasen wichtige Funktionen haben. Die Centrosomen-Reifung und die Aufteilung 
der Chromosomen erfordert die Beteiligung von Polo-ählichen Kinasen. Die Aufteilung 
der Chromosomen scheint dahingegen von Nek2 reguliert zu sein. Eine weitere wichtige 
Rolle in der Aufteilung der Chromosomen, der Orientierung der Chromosomen und  der 
Cytokinese ist für Mitglieder der Aurora Familie postuliert worden. 
 
Die genomische Stabilität wird nicht nur durch den normalen Metabolismus, sondern auch 
durch verschiedenste Chemikalien und Strahlung ständig gefährdet. Um die korrekte 
Zellteilung auch in solchen Fällen zu gewährleisten, bremsen Zellzyklus Kontrollpunkte 
den Zellzyklus ab oder stoppen ihn ganz. Dadurch wird eine Reparatur des Schadens  
möglich. Falls das Ausmass des Schadens zu gross ist, wird die Apoptose eingeleitet. Der 
G2-Kontrollpunkt verhindert, dass Zellen die Mitose beginnen, falls DNS Schäden 
vorhanden sind. Diese Schäden können während der G2-, oder früher in der S- oder sogar 
in der G1-Phase entstanden sein, falls die Schäden dann nicht repariert worden sind. 
Phosphatasen der Cdc25-Familie, welche normalerweise Cdk1 an der G2/M-Grenze 
aktivieren,  werden in solchen Fällen inhibiert und degradiert. Ausserdem vermitteln 
ATM/ATR und Chk1/Chk2  ein Signal, welches zu einer Sequestrierung des Cyclin 
B/Cdk1 Komplexes in verschiedenen subzellulären Kompartimente führt. Kürzlich wurde 
gezeigt, dass Kinasen, wie Plk1, Nek2 und Aurora B, welche in die normale  Spindel 
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Formation involviert sind, auch eine wichtige Rolle in der  Zellantwort auf DNA Schäden 
spielen.  
In dieser Dissertation wurde Etoposid, ein Topoisomerase II Inhibitor, benutzt, um 
Doppelstrangbrüche zu erzeugen, um die Rolle von Aurora A in der DNS-Schadensantwort 
zu untersuchen. Wir haben herausgefunden, dass die Aktivität von Aurora A durch die 
Zellantwort auf Doppelstrangbrüche in der G2/M-Phase reguliert wird (Krystyniak A. et al, 
2006). Nach Behandlung mit Etoposid war die Kinaseaktivität des Enzyms inhibiert und 
sein Proteinlevel stieg an. Die Frage war, ob  Aurora A  abhängig ist von Cdk1 oder 
umgekehrt. Wir haben herausgefunden, dass die Inhibition von Aurora A und Cdk1 
unabhängig voneinander auftritt. Dass die Deaktivierung von Aurora A durch die 
ATM/ATR Kinasen bewerkstelligt wird, konnten wir durch den ATM/ATR Inhibitor 
Koffein zeigen. Ausserdem konnten wir durch Blockierung von Chk1 mit dessen Inhibitor 
UCN01 und siRNA zeigen, dass das Signal an Aurora A über einen Chk1-abhängigen 
Signalweg geleitet wird. Diese Resultate wurden zusätzlich durch Experimente mit einer 
Zelllinie, welche defizient ist in Chk2 (HCT15), verifiziert. Eine Punktmutation in Aurora 
A, S342 zu A, führt zu einem aktiven Enzym, das nicht mehr durch DNS-Schäden 
deaktiviert werden kann. Die S342 Phosphorylierungsstelle wurde bereits früher als eine 
negative Regulationsstelle postuliert.  Diese Stelle liegt direkt neben einem der 
Bindemotive für PP1, einem Aurora A Interaktionspartner. Nach Behandlung mit Etoposid 
verringert sich die Interaktion zwischen diesen zwei Proteinen sehr stark (Krystyniak A. et 
al, manuscript submitted).  Die S342 Mutation zu Alanin, das nicht phosphoryliert werden 
kann, verhindert die Ablösung der Phosphatase vom Komplex. Auf der anderen Seite 
haben wir herausgefunden, dass eine Mutation an derselben Stelle zu einem Aspartat, 
welches eine ständige Phosphorylierung imitiert, die Bildung des Komplexes aus PP1 und 
Aurora A verhindert.  
Zwei verschiedene Ansätze wurden gewählt um die Frage zu untersuchen, ob Aurora A in 
vorhergehend geschädigten Zellen eine mitotische Zellteilung einleiten kann. Transiente 
Transfektion von Zellen mit aktiven Formen von Aurora A (Wildtyp oder S342A, aber 
nicht mit dem kinase-inaktiven S342D Aurora A) hat den Zellen nicht erlaubt die 
Zellzyklusblockade, welche durch DNS Schäden induziert wurde, zu überwinden und mit 
der Mitose fortzufahren. Da eine Transfektion auch experimentelle Nachteile mit sich 
bringt, wie lange Transkriptions- und Translationszeiten oder eine Überexpression des 
Proteins, wurden direkt aktives Protein in Zellen transduziert, welche in der G2 Phase 
arretiert waren, gleich nachdem Doppelstrangbrüche induziert wurden. Dies hat den Zellen 
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ermöglicht sogleich mit der Mitose zu beginnen, obwohl die Schäden noch nicht repariert 
worden waren. Molekular betrachtet ergibt sich, dass aktives Aurora A die 
Wiederaufnahme des  Zellzyklus über eine Reaktivierung von Cdk1 erwirkt. Daher spielt 
Aurora A eine Schlüsselrolle im Signalweg oberhalb von Cdk1 - mindestens solange DNS 
Schäden bestehen. 
Aurora A wird ebenso wie andere Mitglieder dieser Proteinfamilie durch Phosphorylierung 
reguliert. Die Phosphorylierung einer konservierten Aminosäure von Aurora A, Threonin 
288, ergibt eine beträchtliche Steigerung der Kinaseaktivität. Dieser Baustein befindet sich 
in einer Schlaufe in der katalytischen Domäne. Wir konnten zeigen, dass die 
Phosphorylierung von T288 möglicherweise durch einen intermolekularen 
Autophosphorylierungsmechanismus stattfindet. Ausserdem konnten wir zeigen, dass PKA 
in vivo nicht involviert ist in die Phosphorylierung von T288, obwohl diese Kinase früher 
in vitro als dafür verantwortlich befunden wurde. Wie niemand gedacht hätte, wurde eine 
Phosphorylierung dieser Stelle auch in DNS geschädigten Zellen gefunden. Das Ausmass 
der Phosphorylierung war dasselbe wie in mitotischen Zellen. Da Aurora A unter solchen 
Umständen nicht aktiv ist, wie wir durch unsere Kinase Tests zeigen konnten, müssen auch 
andere Mechanismen in der Steuerung der Aktivität eine Rolle spielen.  
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“The world is full of obvious things which nobody by any chance ever observes” 
Arthur Conan Doyle 
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Introduction 
INTRODUCTION 
 
 
1. PROTEIN KINASES AND THE MECHANISM OF 
PHOSPHORYLATION 
 
 
Protein phosphorylation is the most widespread and well-studied signaling mechanism in 
eukaryotic cells. Phosphorylation can regulate almost every property of a protein and is 
involved in all fundamental cellular processes.  
Phosphorylation is controlled by protein kinases, which transfer a phosphate group from a 
donor, ATP or GTP, onto acceptor amino acid in the substrate protein, and protein 
phosphatases that catalyze hydrolysis of the phosphoester bond and release of the free 
phosphate (Ferrari S., 2006). 
 
Ever since the discovery of the fact that reversible phosphorylation regulates the activity of 
glycogen phosphorylase more than 50 years ago, there has been a systematic increase of 
interest in the role of protein phosphorylation in the regulation of protein function. The 
near-completion of a human genome allowed the identification of almost all human protein 
kinases. The most recent kinase phylogenic tree, so-called human kinome consists of 518 
kinases, which accounts for 1,7% of all human genes (Manning G. et al, 2002). The current 
human kinome map is shown in Figure 1.  
 
Most protein kinases belong to a single superfamily named eukaryotic protein kinase (ePK) 
and share a common catalytic domain. However 13 atypical protein kinase (aPK) families, 
encompassing 40 genes, have also been identified. These contain proteins reported to have 
biochemical kinase activity, but which lack sequence similarity to the ePK domain, and 
their close homologs (Manning G. et al, 2002).  
In total 40 aPK in 13 families and 478 ePK, subdivided into 9 major groups, 134 families 
and 189 sub-families, have been identified (see Figure 1.).  
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Figure 1. Human kinome. Most protein kinases belong to a single superfamily of enzymes whose catalytic 
domains are related in sequence and structure. The main diagram illustrates the similarity between the protein 
sequences of these catalytic domains. Each kinase is at the tip of a branch, and the similarity between various 
kinases is inversely related to the distance between their positions on the tree diagram. Most kinases fall into 
small families of highly related sequences, and most families are part of larger groups. The seven major 
groups are labeled and colored distinctly. Other kinases are shown in the center of a tree, colored grey. The 
inset diagram shows trees for seven atypical protein kinase families. These proteins have verified or strongly 
predicted kinase activity, but have little or no sequence similarity to members of the protein kinase 
superfamily (after Manning G. et. All, 2002, property of Cell Signaling Technology) 
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From a structural point of view the ePK catalytic domain comprises 12 sub-domains 
containing highly conserved amino acid residues. All ePKs display a similar fold: they 
consist of a N-terminal lobe, predominantly composed of β-sheets and one single α-helix 
called the C-helix, and a larger C-terminal region that is essentially made up of α-helices 
(Ferrari S., 2006). The amino-terminal lobe contains subdomains I to IV, whereas rest of 
them (subdomains VI to IX) belong to the carboxy-terminal lobe. In between the two lobes 
there is a deep cleft which accommodates ATP (Johnson L.N. and Lewis R.J., 2001). 
Schematic structure of a catalytic domain of ePKs is shown in Figure 2. 
 
 
 
 
 
Figure 2. Structure of protein kinases' catalytic domain. The core catalytic domain of protein kinases 
encompasses 12 subdomains I-IV and VI-IX that participate in the formation of the bi-lobate structure of the 
protein kinase. Conserved residues in the P-loop and in the activation segment are shown. The asterisk 
represents the position of residue(s) in the activation segment the prosphorylation of which triggers kinase 
activation (after Ferrari S., 2006) 
 
 
Bound ATP is capped by a glycine-rich motif called phosphate loop or P-loop, located in 
subdomain I. P-loop displays the conserved motif GXGXΦG, where Φ is in most cases a 
hydrophobic amino acid. Access to the ATP-binding site in many kinases is regulated by a 
peptide located between the conserved motifs DFG and APE in subdomains VII and VIII. 
This region, called the activation segment, being about 20-30 residues in length, contains 
one or two phosphorylation sites critical for activation of the kinase. In most cases 
phosphorylation of the activation segment causes conformational change of the loop, 
resulting with its interaction with the substrate (Huse M. and Kuriyan J., 2002). 
Structurally, the activation segment contains three elements, the Mg2+-binding loop, the 
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activation loop and the P + 1 loop. The first is involved in chelating the Mg2+-ATP 
complex, the second physically contains the site(s) of regulatory phosphorylation, whereas 
the third plays a role in substrate binding (Nolen B. et al, 2004). 
 
Protein kinases, being among the largest families of genes in eukaryotes, mediate most of 
the signal transduction in eukaryotic cells. By modifications of substrate activity, protein 
kinases also control many other cellular processes, including metabolism, transcription, 
cytoskeletal rearrangements and cell movement, apoptosis, differentiation or finally cell 
cycle.  
 
 
 
2. CELL CYCLE 
 
2.1. Cyclin-dependent kinases 
 
The Cyclin-dependent kinases (Cdks) are heterodimeric complexes composed of a catalytic 
kinase subunit and a regulatory subunit. They compromise a family divided into two 
groups based on their roles in the cell cycle progression and transcriptional regulation.  
Members of the first group are the core components of the cell cycle machinery and 
include Cyclin D-dependent kinase 4 and 6, Cyclin E-dependent kinase 2, Cyclin A-
dependent kinase 1 and 2 and Cyclin B-dependent kinase 1. Together, these Cyclin/Cdk 
complexes are the universal cell cycle regulators, with each complex controlling a specific 
transition between the subsequent phases in the cell cycle (Smits V.A.J. and Medema R.H., 
2001). As anticipated above activation of the Cdk requires binding to a specific regulatory 
subunit, termed a cyclin. Originally, cyclins where named after their fluctuating levels 
through the cell cycle. Cyclin binding is, however, not sufficient to trigger Cdk activation. 
Cyclin-dependent kinases are regulated by positive phosphorylation by Cdk-activating 
kinase (CAK) as well as negative phosphorylation events, but also by their association with 
endogenous Cip/Kip or other inhibitors (eg. INK4 – inhibitor of Cdk4). 
 
In contrast to the first group of Cdks, the second group, including Cyclin H-Cdk7 and 
Cyclin T-Cdk9 (pTEFb), promote initiation and elongation of nascent RNA transcripts by 
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phosphorylating the carboxy-terminal domain (CTD) of RNA polymerase II  (Shapiro G.I., 
2006). Schematic explanation of the main role of Cyclin H-Cdk7 and Cyclin T-Cdk9 is 
shown in Figure 3. 
 
 
 
 
Figure 3. Main action of Cdk7 and Cdk 9. The transcriptional Cdks 7 and 9 phosphorylate the carboxy-
terminal domain (CTD) of RNA polymerase II (Pol II), facilitating the initiation of transcription and efficient 
elongation (after G. I. Shapiro, 2006) 
 
 
Inhibition of these Cyclin-dependent kinases preferentially affect mRNAs with short half-
lives, including those encoding anti-apoptotic proteins, cell cycle regulators, and p53, and 
NFκB (nuclear factor kappa B) pathway components, as well as VEGF (vascular 
endothelial growth factor).  
 
Cdk9, which associates with one of the Cyclins T or Cyclin K to form a complex called 
positive transcription elongation factor b (P-TEFb), has also been reported to 
phosphorylate tumor suppressor protein p53, specifically Ser33 on the N-terminus and, 
Ser315 and Ser392 on the C-terminus. However, the precise biological role of this 
phosphorylation remains unclear (Radhakrishnan S. K. and Gartel A. L., 2006) 
 
 
2.1.1. Cyclin-dependent kinases in the cell cycle control 
 
The major mission of the cell division is a faithful and complete duplication of the genome 
followed by an equal partitioning of chromosomes to subsequent cell generations (Lukas J. 
et al 2004).   
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The replication cycle of a typical eukaryotic, somatic cell consists of four phases: G1, S 
(DNA synthesis), G2 and M (mitosis). The result of this process is the generation of two 
daughter cells that are equivalent both in genetic “inside” and in size to the parental cell. 
Early studies with cultured mammalian cells concluded, that progression through the cell 
cycle was governed by several families of cyclin-dependent kinases, each pairing with a 
separate class of cyclin (Nigg E. A., 2001). The cell cycle progression requires a different 
cyclin-dependent kinase for progression through each stage of the cell cycle, as shown in 
the Figure 4. 
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Figure 4. Cell cycle progression with responsible cyclin-dependent kinases (explanation in the text) 
 
 
Extracellular stimuli up-regulate Cyclin D that, upon binding to Cdks 4 and 6, which 
stimulates quiescent cells to enter the cell cycle, whereas Cyclin E/Cdk2 complexes 
regulate the G1/S transition. Cyclin A is induced shortly after Cyclin E and binds Cdk2 in 
S-phase and Cdk1 in G2 and mitosis. Cyclin A is involved in the regulation of S-phase 
entry and later on is found to be important in G2 and M phase. The entry into mitosis is 
under the control of B-type cyclins, which also associate with Cdk1 (Smits V.A.J. and 
Medema R.H., 2001) 
I will describe the particular stages of the cell cycle and the detailed roles of different Cdks 
in more details in following chapters.  
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2.1.1.1. G1 progression and G1-to-S transition 
 
In response to mitotic stimulation, cells synthesize D-type cyclins that assemble with Cdks 
4 and 6 in process that requires contribution of a Cip/Kip family member. Studies using 
cultured cells have indicated that passage through the G1/S transition is regulated by 
Cyclin D/Cdk4/6 and their phosphorylation of retinoblastoma susceptibility protein – Rb. 
In its hypophosphorylated state, Rb prevents progression from G1 to S through its 
interaction with E2F transcription family members. This interaction not only blocks 
transcriptional activation of E2F, but also actively represses transcription through the 
recruitment of histone deacetylases to the promoters of genes required for S-phase entry 
(Harbour J. W. and Dean D. C., 2000). The phosphorylation of Rb in G1 by Cyclin 
D/Cdk4/6 (and subsequently by Cdk2) is a requisite event in reversing the repressive 
effects of Rb and de-repressing transcription of a number of genes required for exit form 
G1 and initiation and completion of S-phase. It has been further suggested that 
phosphorylation of Rb by Cyclin D/Cdk4/6 initiates a subsequent round of phosphorylation 
of the tumor suppressor by Cdk2, which suggests lack of overlapping functions between 
ckd4/6 and Cdk2. Therefore Cyclin D-dependent kinase facilitate G1 progression by first 
phosphorylating Rb, relieving transcriptional repression by the Rb-E2F complex, and by 
sequestering Cip/Kip proteins, facilitating activation of Cyclin E/Cdk2.  
G1 progression is negatively regulated by members of the INK4 family, which are known 
to be specific inhibitors of Cdks 4 and 6. p16 INK4A accumulates as cells age and induces 
G1 arrest during senescence by associating with Cdks 4 and 6 and promoting release of D-
type Cyclins. The subsequent destabilization of D-type cyclins and the redistribution of 
Cip/Kip proteins to Cdk2 contribute to trigger the permanent G1 arrest that precedes 
senescence (Sherr. C.J. and Roberts J. M., 1999).  
 
Cyclin E/Cdk2 mediated Rb phosphorylation disrupts the binding of Rb to E2F, allowing 
E2F activation and therefore the transcription of genes necessary for S-phase entry and 
progression, including Cyclin E itself (Geng Y. et al, 1996). Besides Rb, Cyclin E/Cdk2 
phosphorylates also other targets, including p27Kip1, the degradation of which further 
facilitates S-phase entry (Sheaff R. J. et al, 1997), p220 nuclear protein mapped to ATM 
(Ataxia Teleangiectasia) locus (NPAT) (Zhao J. et al, 1998), which stimulates replication-
dependent histone gene transcription, and nucleophosmin, which regulates centrosome 
duplication (Okuda M. et al, 2000). 
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2.1.1.2. S-phase progression 
 
Our current understanding of the mechanism controlling S-phase progression is centered 
on evidence for a key role played by the Rb pathway. As mentioned above, after Cdk-
mediated phosphorylation of Rb during G1-phase, E2F activity is being freed and E2F 
protein is released. E2F binds to its heterodimeric partner - DP-1 - and thereby directs 
transcription of genes required for the S-phase. This transcription, however, is activated 
only transiently. Further S-phase progression requires the down-regulation of E2F-1 
activity, which is, in part, due to the Cdk-mediated phosphorylation (Kitagawa M. et al, 
1995). 
Several Cdk holoenzymes phosphorylate E2F-1 during the S and G2 phases and participate 
in the appropriately timed neutralization of its activity (Reis T. and Edgar B. A., 2004). 
Cyclin A/Cdk2 stably interacts with the N-terminus of E2F-1 and directs the 
phosphorylation of both E2F-1 and DP-1. Phosphorylation of both components inhibits the 
binding activity of the dimer and releases it from the DNA. On the other hand 
phosphorylation of E2F-1 by Cyclin A/Cdk1 at Ser375 promotes the formation of the 
complex of E2F-1 with Rb, thus keeping the E2F-1 inactive late in the cell cycle (Peeper 
D.S. et al, 1995). Finally, the kinase associated with the RNA polymerase transcription 
factor II (TFIIH), Cyclin H/Cdk7, phosphorylates E2F-1 at Ser408 and Thr433, which then 
promotes its degradation via ubiquitination.  
Scheme of S-phase progression and the involvement of ckd1, 2 and 7 are shown in Figure 
5. 
 
 
 
 
Figure 5. S-phase progression. After Rb protein phosphorylation, E2F, along with heterodimeric DP family 
member partner, directs transcription of S-phase genes. Transcription is activated transiently. E2F-1 activity 
is in part limited by phosphorylation, mediated by Cyclin A-Cdk2, Cyclin A-Cdk1 and Cyclin H-Cdk7. 
Appropriately timed neutralization of E2F activity is required for proper S-phase progression (adapted from 
G. I. Shapiro, 2006) 
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2.1.1.3. Cdk inhibitors 
 
Cdk inhibitors (CKIs) serve as negative regulators of the Cdks (Sherr C.J. et al, 1998). 
CKIs are classified into two distinct families based on their structural and functional 
characteristics. The members of the INK4 family of CKIs (p16Ink4a, p15 Ink4b, p18 Ink4c and 
p19 Ink4d) contain multiple ankyrin repeats and act as negative regulators of Cdk4 and 6 by 
binding to the catalytic subunit and preventing formation of the active Cyclin/Cdk 
complex.  
The Cip/Kip family of CKIs (p21Cip1, p27Kip1 and p57Kip2) is more broadly acting and 
regulates both Cdk4/6 and Cdk2 activity. Each member of the family contains a 
characteristic motif within the amino-terminal region that enables them to bind to both 
cyclin and Cdk subunits. The stoichiometry between Cdks and CKIs is important and 
determines the activity of Rb and the proliferative state of cells.  
 
 
2.1.1.4. G2/M transition 
 
In higher eukaryotes, completion of the G2/M transition requires two Cyclins, A2 and B1, 
that pair with Cdk1. The Cyclin B/Cdk1 complex was originally defined as the maturation-
promoting factor of M-phase promoting factor (MPF), and was identified in meiotic frog 
eggs as a factor capable of inducing M phase in immature G2 oocytes. Regulation of 
Cyclin B/Cdk1 complexes at multiple levels ensures the tight regulation of the timing of 
the mitotic entry. 
After association of the cyclin with its Cdk, the complex is regulated by phosphorylation 
events, which either activate or inhibit its kinase activity. Phosphorylation of the conserved 
threonine (Thr161), localized in the T-loop of the enzyme, by Cdk activating kinase (CAK) 
is required for the activation of Cyclin B/Cdk1 complex. CAK was found to be a 
Cyclin/Cdk complex itself and its composed of Cyclin H and Cdk7. A third component, 
MAT1, is thought to stabilize the Cyclin H/Cdk7 interaction (Fisher R.P., 1994).  
 
During G2-phase, mammalian Cyclin B/Cdk1 complexes are held in an inactive state by 
phosphorylation of Cdk1 at the two negative regulatory sites, threonine 14 (Thr14) and 
tyrosine 15 (Tyr15). Tyr15 is situated in the ATP-binding site of the Cdk1 and 
phosphorylation of this residue interferes with the phosphate transfer to a bound substrate 
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(Atherton-Fessler S. et al, 1993). In contrast, Thr14 phosphorylation inhibits Cdk1 by 
interfering with its ATP binding (Endicott J.A. et al, 1994). Both sites seem to be crucial 
for Cdk1 status since replacement of those amino acids with non-phosphorylable ones 
leads to complete deregulation of Cdk1 and entry into mitosis.  
Phosphorylation of Cdk1-Tyr15 is carried out by the Wee1/Mik1 family of protein kinases. 
A Wee-1 related kinase, Myt1, has been shown to phosphorylate both Thr14 and Tyr15 of 
Cdk1, but with the strong preference for Thr14 (Liu F. et al 1997). Wee1 was shown to be 
a nuclear protein, whereas Myt1 is a membrane-associated protein that localizes to 
endoplasmic reticulum and the Golgi complex (Liu F. et al 1997). The distinct localization 
of both kinases may guarantee inhibition of differently localized subpopulations of Cdk1. 
  
Cdk1 is, on the other hand, positively regulated by Cdc25 family, acting in opposition to 
Wee-1 and Myt1. Members of this family were shown to be dual specificity phosphatases, 
which can dephosphorylate both Thr14 and Tyr15 of Cdk1 (Izumi T. and Maller J.L., 
1993). Dephosphorylation of Thr14 and Tyr15 by Cdc25C in late G2 activates the Cyclin 
B/Cdk1 complex. Cyclin B/Cdk1 in turn phosphorylate Cdc25C, thus forming an 
autocatalytic feedback loop (Izumi T. and Maller J.L., 1993). Full activation of cyclin 
B/Cdk1 triggers the initiation of mitosis.  
 
 
2.1.1.5. M phase  
 
Mitosis is a highly coordinated process in which the two copies of each chromosome 
(sister chromatids) are segregated away from each other to opposite poles of the cell. 
Subsequently, the cell is cleaved between the two newly formed nuclei, leading to 
formation of two independent, daughter cells.  
 
Mitotic division consists of five, tightly regulated phases, namely: prophase, prometaphase, 
metaphase, anaphase and telophase, followed by cytokinesis.  
 
Figure 6 shows chronology of the events in M-phase and the regulatory factors of each 
step. 
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Figure 6. Chronology of M-phase events (details in the text) (from Nigg E.A., 2001) 
 
 
During prophase chromatin condenses into well-defined chromosomes and previously 
duplicated centrosomes migrate apart forming the poles of the future spindle. Chromatin 
condensation requires the combined action of a multisubunit protein complex – condensin 
and of topoisomerase II, the latter being involved in the decatenetion of sister chromatids. 
In late prophase, the microtubules that formed the interphase cytoskeleton are 
disassembled, and highly dynamic microtubules radiate from centrosomes (Ferrari S., 
2006). These mitotic microtubules drive the migration of separated centrosomes, each with 
its pair of centrioles, to the opposite poles of the cell. Nuclear envelope breakdown 
(NEBD) occurs shortly after centrosome separation. During interphase, the nuclear 
envelope is stabilized by a karyoskeletal structure known as the nuclear lamina, but at the 
onset of mitosis this structure disassembles as a consequence of lamin 
hyperphosphorylation (Nigg E. A., 2001). Although lamins can be phosphorylated by 
many kinases in vitro, the predominant kinase triggering mitotic lamina depolimerization 
in vivo is Cyclin B/Cdk1 (Nigg E. A., 1995). 
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During prometaphase microtubules are captured by kinetochores, specialized structures 
associated with centromere DNA on mitotic chromosomes. Chromosomes then congress to 
an equatorial plane, so-called metaphase plate.  
 
Anaphase begins shortly after all chromosomes underwent proper bipolar attachment to the 
spindle. Its onset is characterized by the simultaneous separation of all sister chromatids as 
a result of a loss of sister chromatid cohesion. This separation depends on the degradation 
of an inhibitor called securin, by ubiquitin-dependent proteolysis (Nasmyth K. et al, 2000). 
Securin prevents a protease, called separase, from abolishing sister chromatid cohesion, by 
cutting a component of a multiprotein complex known as cohesin. The other important step 
in cohesin degradation is its phosphorylation, predominantly by Cdk1, but also by Plk1 
(Polo-like kinase 1). 
 
Once the chromosomes have arrived at the poles, nuclear envelopes reform around the 
daughter chromosomes, and chromatin decondensation begins (telophase). 
 
Cytokinesis, the final step of cell division, physically dissociates the two daughter cells 
from each other (Glotzer M., 2005). Cytokinesis starts with contraction of the equatorial 
actomyosin ring, leading to membrane furrowing (Scholey J. M. et al, 2003). As furrow 
ingression completes, the cells remain linked by a cytoplasmic bridge containing the 
remnant of the spindle midzone, the midbody. The actomyosin ring then disassembles 
while resolution of the plasma membrane, called abscission, completes cytokinesis 
(Norden C. et al, 2006).  
 
 
2.2. Other cell cycle kinases involved in mitotic division 
 
Although Cdk1 remains the major regulator of mitosis, recent studies have broadened our 
knowledge of cell division, revealing the presence and importance of other protein kinases. 
A simplified summary is presented in Table 1. 
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Protein kinase    Function 
Cdk1     nuclear membrane breakdown 
     mitotic spindle assembly 
     chromosome condensation 
     APC/C/C regulation 
 
Plk1     centrosome maturation 
     microtubule dynamics 
     chromosome segregation 
     APC/C/C regulation 
     DNA damage recovery 
      
Nek2     centrosome splitting 
 
AurA     centrosome separation 
     Cdk1/Cyclin B1 activation 
 
AurB     chromosome condensation 
     chromosomes bi-orientation 
     cytokinesis 
 
Mps1     centrosome duplication and separation 
     chromatide-spindle attachment  
 
PKA     APC/C/C regulation 
 
PKC     mitotic progression 
 
PI3K     Cyclin B1 expression 
 
Akt/PKB    G2/M checkpoint bypass 
 
Table 1. Protein kinases controlling the onset and progression through mitosis. (after Ferrari S., 2006) 
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Centrosome maturation and chromosome segregation requires the action of Polo-like 
kinases (Plks), whereas separation of centrosomes seems to be regulated by Nek2 (NIMA-
related kinase 2). A role in centrosome separation, chromosome bi-orientation and 
cytokinesis has been postulated for aurora family members (described in details in Chapter 
3). 
 
 
2.2.1. Polo-like kinase 
 
Polo-like kinases (Plks) play important roles in several stages of cell cycle, including 
prophase, metaphase and anaphase of mitosis, cytokinesis and G1/S transition as well as in 
DNA damage response. Flies, budding and fission yeast contain a single Plk family 
member (Polo, Cdc5 and Plo1, respectively), while humans, mice, frogs and worm have 
three Plk members, namely Plk1, Plk2 and Plk3 (nomenclature of human proteins).  
Plk1 is expressed primarily during late G2 and M phases, where it is involved in the 
mitotic machinery regulation. Plk2 expression is mostly in early G1, where it is believed to 
control entry into S-phase, whereas the level of expression of Plk3 seems to be constant 
during cell cycle progression. Plk3 is thought to play a role in several stress response 
pathways, including those activated by DNA damage and spindle disruption (Lowery D.M. 
et al, 2005).  
 
Plk activity is controlled both by the protein abundance and by its intracellular localization. 
During prophase and metaphase, Plk1 localizes to centrosome and spindle pole bodies, 
where it is required for spindle assembly and centrosome maturation, probably by 
phosphorylating some, yet unknown, centrosome associated targets (Goto H. et al 2005), 
(Sumara I. et al, 2004). It participates in bipolar spindle formation, likely by generating the 
force that pulls each chromosome towards the spindle pole (Ahonen L.J. et al, 2005) 
During late anaphase Plk1 re-localizes to the spindle midzone facilitating microtubule 
sliding or some aspects of kinetochore dynamics and eventually come to flank the central 
portion of the cytokinetic bridge (i.e. the midbody) during telophase and cytokinesis. The 
role of Plk1 postulated at those stages is the activation of the anaphase-promoting 
complex/cyclosome (APC/C), which triggers exit from mitosis (APC/C and the regulation 
of cell cycle by protein degradation will be discussed later).  
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The kinase activity of Plk1 was found to be efficiently inhibited after DNA damage in G2 
and mitosis and postulated to be an important target of the DNA damage checkpoint (DNA 
damage checkpoints will be discussed in next chapters), enabling cell-cycle arrest at 
multiple points in G2 and mitosis (Smits V.A.J. et al, 2000), although later studies claimed, 
that Plk1 is not a principal regulator or mediator of the mitotic DNA damage response 
(Yuan J-H. et al, 2004). There is no doubt, however, that Plk1 controls recovery from a G2 
DNA damage-induced arrest by mediating degradation of Wee1 (van Vugt M.A.T.M. et al, 
2004 and 2005). 
Among Plk1 substrates are: Cdc25C (Toyoshima-Marimoto F. et al, 2002), BRCA2 (Lin 
H.R. et al, 2003), Myt1 (Nakajima H. et al, 2003), Cyclin B (Toyoshima-Marimoto F. et al, 
2001), Wee1 (Sakchaisri K. et al, 2004) and p53, the function of which Plk1 inhibits (Ando 
K. et al, 2004).  
 
 
2.2.2. Nek2 kinase 
  
Nek2 (NIMA-related kinase 2) is a mammalian serine/threonine kinase known to posses 
high sequence homology to NIMA (Never In Mitosis A), a kinase shown to be necessary 
for mitotic entry in Aspergillus nidulans (Fry A.M. et al, 1995). Nek2 activity is regulated 
by autophosphorylation, but also its physical association with protein phosphatase 1 (PP1) 
has been reported (Helps N.R., et al, 2000). Nek2 seems to be cell-cycle regulated: the 
protein level is low in G1 and increases throughout S and G2 (Fry A.M. et al, 1995), then – 
in prometaphase to metaphase of mitosis - the protein is rapidly degraded in an 
APC/C/cyclosome dependent manner.  
Nek2 localizes to the centrosome where, when overexpressed, induces centrosome splitting 
by phosphorylating C-Nap1, its interacting partner (Fry A.M. et al, 1998). The possible 
inhibition of both Nek2 kinase activity and protein level, as contribution to the cell cycle 
arrest upon DNA damage, has been shown by a single study (Fletcher L. et al, 2004). 
 
 
2.3. Ubiquitin-mediated protein degradation in the regulation of cell cycle 
 
Ubiquitin-dependent proteolysis by the proteasome plays an essential role in a number of 
key biological processes, including cell cycle progression, transcription and signal 
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transduction. In many cases the target protein is first marked for degradation or processing 
by phosphorylation. The phosphorylated protein is then recognized and ubiqiutinated in a 
process that requires three proteins. Ubiquitin is first attached to an ubiquitin-activating 
enzyme (E1) in an ATP-dependent reaction to form a high-energy thiolester bond. The 
ubiquitin is then transferred from the E1 protein to an E2 ubiquitin-conjugating enzyme, 
which functions in conjunction with an E3 protein to link ubiquitin to lysine residues in the 
targeted protein. A specific lysine residue in the conjugated ubiquitin is then attached to a 
second ubiquitin, and reiteration of this process results in the assembly of a polyubiquitin 
chain. The polyubiquitinated protein can then be recognized by the 26S proteasome and 
degraded or processed (Maniatis T., 1999). 
E1 and E2 proteins have been identified and characterized, and the later has been shown to 
comprise a family of related proteins. In contrast, much less is known about E3 enzyme.  
 
Progression through a eukaryotic cell cycle requires tight control of the activity of different 
factors. Evidence obtained so far has shown that one of the possible ways to control cell 
cycle progression is to regulate the abundance of key factors, either by controlling their 
expression or degradation. The list of cell cycle regulatory proteins that are targeted for 
turnover by ubiquitin-mediated proteolysis is extensive. Some noteworthy examples are 
listed in Table 2. 
 
Generally, targeted proteins fall into two categories: those for which ubiqiutin-mediated 
destruction is central to their proper function – for example proteins that temporarily halt 
cell cycle progression, but need to be destroyed in order for cell cycle to resume, and those 
whose expression is limited to a specific cell cycle window by proteolysis, but whose 
destruction does not seem to be intrinsic to function (Reed S.I., 2003). 
 
In terms of the ubiquitylation machinery, the targeting for turnover of cell cycle regulatory 
proteins seems to be mediated through two distinct alternative strategies: activation of the 
target itself, or activation of the protein ubiquitin ligase that transfers ubiquitin to a 
particular class of target. The former strategy allows for selectivity that is dependent on the 
regulatory context of individual target molecules, whereas the latter allows for concerted 
and total destruction of populations of target molecules at particular points in the cell cycle 
(Reed S.I., 2003). 
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Table 2. Cell cycle targets for ubiquitin-mediated proteolysis (after Reed S.I., 2003) 
 
 
Most commonly, targeted-activated destruction, in the context of the cell cycle, is carried 
out by a class a protein-ubiquitin ligase known as SCF (for Skp1/Cul1/F-box), whereas 
alternative forms of a ligase that is known as the anaphase-promoting complex/cyclosome 
(APC/C) are themselves activated through signaling pathways that are intrinsic to the cell 
cycle.  
Figure 7 shows which of the ligase classes is responsible for the various cell cycle targets 
of ubiquitylation. 
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Figure 7. Key cell-cycle regulatory 
proteins targeted by ubiquitin-
mediated proteolysis. (after Reed S.J., 
2003) 
 
 
The E3 ubiquitin ligases can be classified into HECT domain, Ring-H2-finger domain and 
U-box domain superfamilies (Ang L.X., Harper J.W., 2005). Both, SCF and APC/C are 
members of the Ring-H2-finger-containing E3 ubiquitin-ligase family. SCF complexes are 
used throughout the cell cycle, whereas APC/C functions primarily during mitosis and G1 
phase. 
 
 
 
 
 
 
 
Figure 8. Comparison of the 
APC/CCdc20 and the SCF ubiquitin 
ligases. Proteins belonging to the 
same family are identically colored. 
Interaction of the different APC/C 
subunits have been represented 
taking into account the existent 
results on the association between 
different APC/C components. 
(models by Castro A. et al, 2005). 
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SCF and APC/C differ from each other also in terms of general structure, the APC/C being 
much larger and composed of different subunits. APC/C and SCF both contain a Cullin, a 
Ring-H2-finger and a WD40 subunit. The cullin and the Ring-H2-finger proteins form a 
minimal ubiquitin-ligase module of both E3, and are required for E2 tethering. The APC/C 
contains additional subunits, such as the tetratricopeptide containing proteins and the Doc 
protein.  
Figure 8 shows schematic comparison of SCF and APC/C composition. 
 
 
2.3.1. SCF complex 
 
The SCF complex has three primary subunits: Skp1, Cullin and Rbx1/Roc1. This complex 
can interact with a variety of proteins containing an F-box motif and with Cyclin F, which 
interacts with Skp1 directly (Bai C. et al, 1996). The Cul1/Rbx1 components form the E3 
ubiquitin ligase core that associates with E2 ubiquitin-conjugating enzymes. F-box proteins 
directly recruit ubiquitination substrates and bridge the interaction between the E2 and the 
substrate (Feldman R.M. et al, 1997). Thus, the identity of the F-box protein determines 
the target of the SCF. There are a variety of F-box proteins, including subfamilies with 
WB40 domains (Fbw) or with leucine-rich repeats (Fbl) (Cenciarelli C. et al, 1999). 
Moreover, F-box proteins often recognize their substrates in a manner dependent upon 
particular modification, for example phosphorylation or glycosylation (Feldman R.M. et al, 
1997).  
Within the context of a complex cellular environment, phosphorylation allows for substrate 
discrimination by SCF complex due to its ability to specifically recognize phosphorylated 
motifs called phosphodegrons. A phoshodegron is defined as one or a series of 
phosphorylated residues on the substrate that directly interact with a protein-protein 
interaction domain in an E3 ubiquitin ligase (e.g. an F-box protein), thereby linking the 
substrate to the conjugation machinery (Winston J.T. et al, 1999). Additionally, 
phosphorylation allows temporal regulation of substrate degradation, even if SCF 
complexes are constitutively active throughout the cell cycle. 
Figure 9 presents examples of protein degraded by SCF in the phosphorylation-dependent 
fashion.  
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Figure 9. Multiple kinases regulate the 
degradation of SCF substrates, including that of 
β-TRCP. The priming kinase, depicted in italics, 
first phosphorylated the substrate to prime it for 
subsequent binding to the second kinase. The 
second kinase completes formation of the 
phoshodegron consensus motif (in bold) by 
phosphorylation residues that can now be directly 
recognized by β-TRCP. The absence of the priming 
activity results in an inability of the second kinase 
to phosphorylate efficiently the phosphodegron  , 
as well as the stabilization of the substrate. The 
absence of the second kinase activity also prevents 
efficient substrate turnover, as the phosphodegron 
motif remains unphosphorylated and 
unrecognizable by β-TRCP (after Ang X.L. and 
Harper J.W., 2005). 
 
 
The SCF complex itself is also subject to post-translational modifications in the form of 
neddylation on the Cullin subunit (Lammer D. et al, 1998). Neddylation describes the 
linkage of Nedd8 – a small 76-residue protein with sequence similarity to ubiquitin – to a 
lysine residue of the substrate. Neddylation occurs on the winged-helix B domain of 
Cullin, which is part of the domain that forms a globular tail binding Rbx1 and E2-
conjugating enzyme (Zheng N. et al, 2000). Although Nedd8 conjugation is known to 
dramatically increase ubiquitin transfer by E2s bound to the Rbx1/Cullin complex, the 
exact mechanism of this stimulation remains unknown. 
 
 
2.3.2. APC/Cyclosome 
 
The APC/C is a large protein complex containing at least 11 core subunits (Zachariae W. et 
al, 1998), which can further associate with at least three known different activators. The 
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majority of those subunits are stably associated throughout the cell cycle, except for the 
different activators whose binding to APC/C is cell cycle regulated.  
Subunits and activators of the APC/C are presented in Table 3. 
 
Core subunit     Motif 
APC/C1/Tsg24     Rpn1/2 homology 
APC/C2     Cullin homology 
APC/C3/Cdc27     Tetratricopeptide repeats 
APC/C4       
APC/C5 
APC/C6/Cdc16     Tetratricopeptide repeats 
APC/C7     Tetratricopeptide repeats 
APC/C8/Cdc23     Tetratricopeptide repeats 
 
APC/C10     Doc domain 
APC/C11     Ring-H2-finger domain 
Cdc26       
Activators     Motif 
Cdc20/p55cdc     WD40 repeats 
Cdh1      WD40 repeats 
 
Table 3. Subunits of the APC/C in vertebrate cells (after Castor A. et al, 2005). 
 
 
The APC/C is fully active only when it is bound to the activator, mainly Cdc20 or Cdh1, 
resulting in distinct assemblies called APC/CCdc20 or APC/CCdh1. Since Cdc20 and Cdh1 
can bind to APC/C substrates, they may activate ubiquitination reactions by recruiting 
substrates to the APC/C, but the details of the process are largely unknown.  
 
APC/C-mediated ubiquitination depends on either one or three rather poorly defined 
sequence elements in the substrate, the destruction box (D-box), the KEN box and recently 
described GxENbox (Castro A. et al, 2003). The D-box was found to be necessary to 
induce degradation of Cyclin B (Glotzer M. et al, 1991), Cyclin A (Lorca T. et al, 1992), 
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Nek2 (Hames R.S. et al, 2001) and Aurora A (Castro A. et al, 2002). The KEN box 
sequence is present in the APC/C activator Cdc20, which is itself and APC/CCdh1 substrate.  
A particularly interesting case is degradation of Aurora A. Proteolysis of this protein is 
exclusively mediated by APC/CCdh1 and requires the presence of a double degradation 
motif: the D-box and a new degradation signal, named DAD (D-box Activating Domain) 
or A-box. Mutation of either of these two domains prevents destruction of Aurora A 
(Castro A. et al, 2002), (Littlepage L.E. and Ruderman J.V., 2002). 
Ubiquitin-dependent degradation of the cell cycle factors induced by the APC/C is a key 
mechanism used by the cell to tightly regulate different transitions throughout cell division. 
Thus, the APC/C orchestrates mitosis by controlling anaphase entry and progression, exit 
of mitosis and G1 phase. Moreover it plays an important role in the formation of the 
prereplicative complexes required to induce DNA replication (Castro A., 2005). 
Figure 10 shows the involvement of APC/C in degradation of different cell cycle proteins 
with activator distinction.  
 
 
 
 
 
 
Figure 10. APC/CCdc20 and APC/CCdh1-dependent degradation of different cell cycle proteins. 
APC/CCdc20 is first activated at the prometaphase-metaphase transition, where it will induce Cyclin A and 
Nek2 degradation. This complex is also responsible for the subsequent degradation at metaphase of Cyclin B, 
Xkid and securin and at the anaphase of the kinesin Kip1 and Cin8. From late anaphase until mitotic exit and 
throughout G1 phase, the degradation of all these proteins is insured by APC/CCdh1. Moreover, this complex 
will first induce proteolysis of Cdc20, Prc1, Tome-1, Plk1 and Aurora A at mitotic exit and subsequent 
degradation of Orc1, Cdc6 and Geminin in early G1 (details in the text) (after Castro A., 2005). 
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Entry into anaphase is marked by the initiation of sister chromatid separation. The APC/C-
dependent degradation of securin enables separase activation and, as a consequence, 
cleavage of the cohesin complex (Uhlmann F. et al, 2000). Proteolysis of securin is 
ensured by APC/CCdc20 before anaphase onset, but its degradation is maintained until the 
end of G1 by APC/CCdh1.  
APC/C also induces degradation of several factors essential for spindle-pole separation and 
spindle disassembly, for example Xkid. Xkid plays an important role in prometaphase by 
maintaining the polar ejection force, that pushes chromosomes away from the pole and that 
mediates chromosome congression (Antonio C. et al, 2000). However, subsequent 
proteolysis of this protein is also essential to allow chromosome movements to the spindle 
poles during anaphase. Xkid degradation is mediated both by APCCdc20 and APCCdh1. Two 
other motor proteins, the kinesin Kip1 and Cin8, are proteolysed by APC/C. They are both 
required to separate the spindle poles during spindle assembly and metaphase and their 
subsequent degradation at anaphase is essential to allow progression through this phase. 
Degradation of Cyclin B, the first known APC/C substrate, begins at metaphase and 
continues throughout mitosis and G1. Both complexes APC/CCdc20 and APC/CCdh1 mediate 
its degradation. Cyclin B proteolysis is required to inhibit Cdk1 activity and as a 
consequence to induce different cell processes, such as sister chromatid separation, 
disassembly of the mitotic spindle, chromosome decondensation, cytokinesis and re-
formation of the nuclear envelope (Murray A.W. and Kirschner M.W., 1989), (Luca F.C. 
et al, 1991), (Gallant P. and Nigg E.A., 1992), (Holloway S.L. et al, 1993), (Surana U. et 
al, 1993).  
Another substrate, whose degradation is carried out by APC/CCdh1, necessary for mitotic 
exit is Plk1. It has been shown that destruction of this protein is required to inactivate 
APC/C-dependent degradation of mitotic cyclins as cells enter S-phase. 
The main substrate of APC/C during G1 phase is one of its own activators - Cdc20. Cdc20 
proteolysis by APCCdh1 induces APCCdc20 inactivation and allows the switch from 
APC/CCd20 to APC/CCdh1. APC/CCdc20 is active in the presence of high Cyclin B/Cdk1 
activity, whereas Cdh1 phosphorylation by this complex prevents APC/Cdh1 association, 
and as a consequence, APC/CCdh1 activation. Once Cyclin B degradation has started at 
metaphase, Cyclin B/Cdk1 decreases, Cdh1 is dephosphorylated, APC/CCdh1 is activated 
and Ccd20 is degraded. At this stage of the cell cycle, APCCdh1 takes over the degradation 
of mitotic cyclins, preventing their premature accumulation and premature entry into S-
phase. 
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Schematic representation of regulation of activity of different APC/C complexes is shown 
in Figure 11. 
 
 
 
 
 
Figure 11.Temporal pattern of APC/Ccdc20 and APC/CCdh1 regulation throughout the cell cycle. (details 
in the text) (after Castro A. et al, 2005). 
 
 
Besides Cdc20, Aurora A kinase is also degraded by APC/C during G1 phase. This 
proteolysis is exclusively mediated by APC/CCdh1, as I have described previously.  
 
Phosphorylation of APC is one of the mechanisms used by cell to modulate its activity. 
The core subunits of APC: Apc1, Apc3/Cdc27, Apc6/Cdc16, Apc7 and Apc8/Cdc23, are 
phosphorylated during mitosis (Peters J.M. et al, 1996). This phosphorylation modulates 
Cdc20 binding to the APC and APC/C activity. Three different kinases have been 
described to phosphorylated APC: Cyclin B/Cdk1, Plk1 and PKA (Kotani S. et al, 1998), 
(Golan A. et al, 2002). Phosphorylation of core subunits by Cyclin B/Cdk1 increases 
Cdc20 binding and thereby APC/C activity (Kraft C. et al, 2003), whereas Plk1 
phosphorylation does not influence neither Cdc20 binding nor APC/C activity. However, 
combination of both, Plk1 and Cyclin B/Cdk1 phosphorylation acts synergistically to 
increase APC/C ubiquitination abilities. In vitro phosphorylation of APC/C by PKA 
inhibits ubiquitination of Cyclin B even in the presence  of regulatory factors Cdc20 and 
Cdh1 (Kotani S. et al, 1998).  
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Among negative regulators of APC/C on can find spindle checkpoint-dependent inhibitors, 
like Mad2, BubR1 and Mad2L2. Mad2 and BubR1 are known to inhibit APC/CCdc20 (Fang 
G., 2002), whereas Mad2L2 was shown to specifically act on APC/CCdh1. Besides those, 
there are other two inhibiting proteins known: Emi1 (Hsu J.Y. et al, 2002), inhibiting both 
APC/CCdc20 and APC/CCdh1 by directly binding to the activators, and RASSF1 interacting 
exclusively with Cdc20 (Song M.S. et al, 2004). 
 
 
 
2.6. Cell cycle checkpoints 
 
Cell cycle checkpoints pathways mediate progression through the cell cycle and contribute 
to genomic stability, which is dependent on the fidelity of both DNA replication and 
chromosome segregation. Genomic stability is under constant threat from chemicals, 
radiation and normal cellular metabolism. Defects in the cell cycle checkpoint pathways 
are associated with an array of phenotypes in mammals – including cancer predisposition 
and neurodegeneration – consistent with the notion that checkpoint responses are critical 
for appropriate decision leading to cell survival or cell death. 
Distinct checkpoints have been identified and characterized and the brief overview of them 
will be presented in the next chapters. 
 
 
2.6.1. Spindle assembly checkpoint 
 
The spindle assembly checkpoint delays sister chromatid separation until all chromosomes 
are properly aligned on the spindle. The checkpoint monitors the attachment of 
microtubules to kinetochores and generation of tension that results from bipolar attachment 
of sister chromatids.  
Studies using mutant yeast strains have led to the identification of several kinases involved 
in spindle assembly checkpoint, namely Mps1, Bub1 and Bub3, as well as proteins Mad1, 
Mad2 and Mad3, which points to the important role of phosphorylation in the regulation of 
this checkpoint. According to our current understanding, structural changes, induced by 
microtubule attachment and tension, are translated, through phosphorylation, into a 
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biochemical signal. It has been proposed that interaction between the kinesin-related 
protein CENP-E and the kinase BubR1 is essential for this translation (Chan G.K. et al, 
1999), (Yao X. et al, 2000), (Abrieu A. et al, 2000). How this regulates the kinetochore 
association of Mad proteins is unknown. However, unattached kinetochores are believed to 
function as sites of continuous assembly and release of Mad-Cdc20 complexes that prevent 
the activation of APC/CCdc20. On attachment of the last kinetochore, the production of 
inhibitory Mad2-Cdc20 complexes ceases, allowing Cdc20 to dissociate from Mad2 and 
activate APC/C/C. As a result securin is degraded and anaphase ensured. 
Figure 13 represents schematic model of spindle assembly checkpoint. 
 
 
 
 
Figure 13. The spindle assembly checkpoint. One model holds that interaction between the kinesin-related 
protein CENP-E and BubR1 translate structural information (the presence or absence of appropriate 
microtubule-kinetochore interactions) into a chemical signal. These events regulate both recruitment of 
Mad1-Mad2 complexes to unattached kinetochores and the release of "conformationally altered Mad2" 
(represented by Mad2*). Mad2* then blocks a productive interaction between Cdc20 and APC/C, thereby 
preventing the degradation of securin and the cleavage of cohesin by separase. On attachment of the last 
kinetochore, the production of Mad2* drops, what ensues activation of APC/CCdc20. In addition to Bub1 and 
BubR1, activated MAP kinase (Mitogen Activated Kinase), Plk1 and Aurora B have been also detected at 
kinetochores, suggesting that these enzymes may function in either checkpoint signaling or silencing (after 
Nigg E.A., 2001). 
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At present it is not understood why mammalian cells express two Bub1 family members: 
Bub1 and BubR1. Both of them are required for checkpoint signaling (Chan G.K. et al, 
1999), (Taylor S.S. and McKeon F., 1997), both are recruited to unattached kinetochores 
and they seem not to be redundant. Bub1 and BubR1 are recruited to the kinetochores in 
association with Bub3, a WD-repeat-containing substrate (Taylor S.S. et al, 1998), but 
what is the exact function – regulatory or effectory - of Bub3 is not known. Similarly the 
precise function of Mps1 family kinase needs to be resolved.  
 
 
2.6.3. Spindle orientation (positioning) checkpoint  
 
The spindle positioning checkpoint enforces the correct orientation of the elongation 
spindle to ensure that cleavage occurs in the right plane and only after complete separation 
of sister chromatids.  
Evidences for the existence of spindle orientation checkpoint are coming from studies in   
budding yeast. Its silencing requires that a spindle pole body associates productively with 
the cortex of the budding cell, thus establishing a dependency between correct spindle 
positioning and mitotic exit (Hoyt M.A., 2000). The first identified component of this 
pathway was Bub2p, a spindle-pole-associated subunit of a two-component GTPase-
activating protein (GAP). The latter down-regulates the activity of a small GTPase – 
Temp1p – that in turn functions at an early step in a pathway controlling mitotic exit. 
Downstream of active Temp1p, several kinases cooperate in so-called mitotic exit network 
(MEN) to activate Cdc14p phosphatase (Hoyt M.A., 2000). Cdc14p then acts not only as 
the activator of APC/CCdh1, but also dephosphorylates the Cdk1 inhibitor Sic1p, causing its 
stabilization, and the transcription factor Swi5p, which in turn enhances the Sic1p 
production. Therefore, inactivation of Cdk1 is ensured by three complementary 
mechanisms.  
Gene products homologous to most components of the MEN pathway in Saccharomyces 
cerevisiae have also been found in fission yeast, although there is no evidence yet, that SIN 
(septation initiation network) plays a part in controlling Cdk1 inactivation. This would 
indicate that homologous gene products control partly distinct processes in two yeast.  
The existence of spindle positioning checkpoint in organisms other than yeast still remains 
to be determined.  
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2.6.4. DNA structure/DNA damage checkpoints 
 
The key components of mammalian DNA structure checkpoints' network can be divided 
into five categories, based on the position and general function in the network. 
1. Sensors – among the plausible candidates for checkpoint sensors are the Rad9-Hus1-
Rad1, so-called 9.1.1 complex, PCNA-like sliding clamp complex, the Rad17-RFC 
clamp loading complex and possibly the Mre11-Rad50-Nbs1 or MNR nuclease 
complex (Melo J. et al, 2002), (Petrini J.H. and Stracker T.H., 2003). 
2. Mediators – include BRCA1, MDC1/NFBD1, 53BP1 and Claspin (Petrini J.H. and 
Stracker T.H., 2003). 
3. Atypical signal transduction kinases – kinases of the phosphatidylinositol 3-kinase 
(PI3K)-like family, include ATM and ATR kinases (Abraham R.T., 2001), (Siloh Y., 
2003). 
4. Effector kinases – distal serine/threonine signal transduction kinases, represented by 
Chk1 and Chk2 (Bartek J. and Lucas J., 2003) 
5. Effector proteins – large and diverse group encompassing cell cycle regulators such 
as Cdc25 phosphatase, various DNA repair proteins, transcription factors such as p53 
and E2F, chromatin components and regulators such as histone H2AX and Tlk 
kinases, and others (Zhou B.B. and Elledge S.J., 2000), (Donzelli M. and Draetta 
G.F., 2003). 
 
 
2.6.4.1. Checkpoint kinases 
 
A central role for two groups of protein kinases, the ATM/ATR group and the Chk1/Chk2 
group, in mediating the cellular responses to DNA damage has been established.  
 
 
2.6.4.1.1. ATM/ATR 
 
Both ATM (Ataxia Teleangiectasia Mutated) and ATR (ATM and Rad3-Related) belong to 
a group displaying homology to lipid kinases of the phosphatidylinositol-3-kinase (PI3-K) 
family. The yeast counterparts include Tel1 (Schizosaccharomyces pombe and 
Saccharomyces cerevisiae), Mec1 (S. cerevisiae) and Rad3 (S. pombe). The importance of 
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this group of kinases in the response to DNA damage is emphasized by the fact that 
mutations in the human ATM gene are responsible for the recessive disorder ataxia 
teleangiectasia (AT), which results in progressive neurodegeneration, immune deficiency 
and the predisposition to cancer. These phenotypes all result from the inability of cells to 
properly handle damaged DNA (Jeggo P.A. et al, 1998). 
The ATM kinase seems to primarily be activated following DNA damage whereas the 
ATR kinase seems to be critical for cellular responses to the arrest of DNA replication 
forks (Siloh Y. and Kastan M.B., 2001), (Abraham R.T, 2001). Many types of DNA 
damage, however, result both in the direct damage of the DNA and the arrest of DNA 
replication forks, therefore ATM and ATR seem to participate together in many cellular 
responses and complex joint response must be coordinated. Replication-fork arrest 
stimulates the initiation of cellular ATR activity, whereas DNA damage directly activates 
ATM and leads to replication-fork arrest, thereby also activating cellular ATR kinase.  
 
ATM is an extremely large protein with predicted molecular mass of 350 kilodaltons. 
Patients, mice and cells lacking ATM are viable, suggesting that ATM kinase is not 
essential for critical cellular functions such as normal cell cycle progression or 
differentiation (Siloh Y. and Kastan M.B., 2001).  
ATM kinase activity is minimal or low in unstressed cells and primarily is engaged to help 
cells deal with cellular stress that affect DNA or chromatin structure. ATM is present there 
as a homodimer in which the kinase domain is physically blocked by its tight binding to an 
internal domain of the protein surrounding serine 1981. The introduction of a DNA double 
strand break leads to a conformational change in the ATM protein, which stimulates the 
kinase to autophosphorylate serine 1981, causing the dissociation of the homodimer 
(Bakkenist C.J. and Kastan M.B., 2003). The activated monomer is now able to 
phosphorylate its numerous substrates: p53, NBS1 (Nijemegen breakage syndrome 1), 
BRCA1 (breast cancer 1) or SMC1 (structural maintenance of chromosome 1). The 
conformational change, which induces extremely rapid autophosphorylation of ATM, does 
not seem to require the binding of ATM to the site of DNA damage, but instead results 
from some change in higher-order chromatin structure that the ATM dimer can sense at 
some distance away from the site of the DNA break. The exact nature of this "sensing" is, 
however, not known. Recent observations postulate a role of MRE11/RAD50/NBS1 
complex in the activation of ATM upon ionizing radiation (Uziel T. et al, 2003), (Carson 
C.T. et al, 2003). This role was shown to be mainly binding to ATM and helping its 
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translocation to the sites of DNA damage (Lee J.H. and Paull T.T., 2004). Once recruited 
to the DNA break, the activated ATM can then phosphorylate critical substrates like 
NBS1, BRCA1 and SMC1, which accumulate at these sites. If ATM is activated, but fails 
to translocate to the site of the DNA break (in the absence of NBS1 or BRCA1) it can still 
phosphorylate its nucleoplasmic substrates such as p53.  
 
ATR is a large protein, with a predicted molecular mass of 301 kilodaltons. Unlike in the 
case of ATM, cell and animals lacking ATR seem to be non-viable (Brown E.J. and 
Baltimore D., 2003). These observations suggest that ATR is required for normal 
progression through  the cell cycle, even in the absence of cellular stress. ATR has been 
reported to play a role in normal progression of DNA replication forks (Shechter D. et al, 
2004) as well as in other types of cellular stress, like hypoxia (Hammond E.M. et al, 2002) 
and in cellular response to DNA-replication inhibitors (Hekmat-Nejad M. et al, 2000). 
Finally, ATR seems to be engaged in the response to DNA breaks, possibly compensating 
for ATM, since many ATM substrates get phosphorylated after induction of double strand 
breaks in cells lacking ATM proteins (Krystyniak A. unpublished results).  
It seems that ATR kinase may be constitutively ready to phosphorylate substrates but have 
its cellular function controlled by sub-cellular localization. ATR exists, independently on 
the exposure to stress, in a complex with the ATR-interacting protein (ATRIP) (Cortez D. 
et al, 2001). The observation has been made that replication protein A (RPA), a single-
stranded DNA-binding protein involved in DNA replication, stimulates the in vitro binding 
of ATRIP to ssDNA. This has led to a model in which ATR becomes localized to sites of 
replication fork arrest by means of binding of ATRIP to RPA (Zou L. and Elledge S.J., 
2003). Any stimulation or stress that leads to an abnormal stretch of single stranded DNA, 
such as an arrested replication fork, would be decorated with RPA. The accumulation of 
RPA would then lead to the recruitment of ATRIP protein together with its binding partner 
ATR. Once active ATR kinase is localized to the single stranded DNA region, it can 
phosphorylate its critical substrates, such as RAD17 and Chk1. As with ATM, the presence 
of an active ATR kinase in the cells is not sufficient for ATR to carry its cellular functions. 
In addition to ATR, several other proteins must be recruited to the sites of ssDNA as well. 
These include the clamp loading Rad17-RFC complex, RSR, which participates in the 
loading of the Rad9-Hus1-Rad1 sliding clamp into chromatin, and the claspin protein, 
which is independently recruited to chromatin (Ellison V. and Stillman B., 2001), (Osborn 
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A.J. et al, 2002). All these events are required for the phosphorylation of Chk1 by ATR 
and for the activation of the appropriate cell cycle checkpoint.  
 
Figure 14 presents a model of ATM and ATR activation. 
 
 
 
 
 
Figure 14. Scheme of mechanisms that lead to the induction of ATM- and ATR-directed cellular 
activities. DNA strand breaks lead to the dissociation of the inactive ATM dimer. The appropriate 
localization of both the ATM monomer and the ATM substrates is modulated by several proteins, including 
the MRN complex, MDC1, 53BP1 and BRCA1. The ATR/ATRIP complex is recruited to sites of ssDNA, 
perhaps by RPA. Optimal substrate phosphorylation and the engagement of cell cycle arrest depends on other 
proteins such as claspins, the RSR complex and the 9-1-1 complex.  
 
 
 
2.6.4.1.2. Chk1/Chk2 
 
The second group of kinases consists of serine/threonine kinases Chk1 and Chk2. Chk1 
was first identified in Schizosaccharomyces pombe and shown to be required for cell cycle 
arrest in response to DNA damage. Homologues have been found in S. cerevisiae, 
mammals, Xenopus and flies (O'Connell M.J., et al, 2000). Chk2 is the mammalian 
homologue of Cds1 in S. pombe and Xenopus and Rad53 in S. cerevisiae. Mutations in 
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human Chk2 have been uncovered in patients predisposed to cancer with Li-Fraumeni 
syndrome (LFS) (Bell D.W. et al, 1999). 
 
Chk2 is a relatively stable protein, with a half-life longer than six hours, which is 
expressed and can be activated in all phases of the cell cycle. As mentioned above, several 
kinds of genotoxic stresses can activate the ATM kinase, which in turn phosphorylates the 
N-terminal regulatory domain of Chk2, at many sites, the most prominent being threonine 
68 (Bartek J. et al., 2001). This in turn promotes homodimerization and intermolecular 
transphosphorylation of Chk2 on its C-terminal kinase domain ( Ahn J.Y. et al., 2002), (Xu 
X. et al., 2002), (Lee C.H. and Chung J.H., 2001), a modification required for a full 
activation of Chk2 toward heterologous substrates (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Regulation of Chk2 activity by 
phosphorylation. (by Bartek J. and Lukas 
J., 2003). 
 
 
A recent report indicates that the ATM-dependent phosphorylation of Chk2 cannot occur 
freely in the nucleoplasm, but requires a specific DSB-associated adaptor protein(s) (Lukas  
J. et al., 2003). In addition, other checkpoint proteins may co-regulate the physiological 
velocity and/or timing of Chk2 activation. These factors include a DSB-interacting protein 
(53BP1), DNA ends-processing MRN nuclease complex (Mre11/Rad50/Nbs1), and its 
newly identified binding partner Mdc1. 
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By contrast to Chk2, Chk1 protein is unstable, with a half-life of less than two hours and 
its expression is restricted to S and G2 phases of the cell cycle. Activation of ATR, by 
mainly stalled replication, induces phosphorylation of its main substrate Chk1 (Feijoo C. et 
al., 2001), (Heffernan T.P. et al., 2002), (Shiloh Y., 2003). Several recent studies show that 
ATM can also phosphorylate Chk1 in cells exposed to IR, although to a lesser extent 
compared to the ATR-mediated effect after other types of DNA damage (Gatei M. et al., 
2003). Both ATR and ATM target the SQ-rich C terminus of Chk1, including serines 317 
and 345, respectively. These phosphorylations may directly lead to Chk1 activation. 
Optimal activation of Chk1 also requires a cooperative action of other factors including the 
multifunctional BRCA1 tumor suppressor (Yarden R.I. et al., 2002), the claspin adaptor 
molecule, and the PCNA-like DNA sliding clamp (Rad9/Rad1/Hus1) together with its 
loading factor (Rad17) (Figure 17).  
 
 
 
 
 
 
 
 
 
Figure 16. Regulation of Chk1 activity. 
(by Bartek J. and Lukas J., 2003). 
 
 
 
Following their activation, Chk1 and Chk2 phosphorylate unique and overlapping 
downstream effectors that further propagate the checkpoint signaling. Depending on the 
type of stress, extent of DNA damage, and cellular context, this leads to switch to the 
stress-induced transcription program (E2F1, BRCA1, p53), direct or indirect initiation of 
DNA repair (BRCA1, p53), acute delay (degradation of Cdc25A) and/or sustained block 
(Cdc25C, p53, Plk3) of cell cycle progression, apoptosis (Pml1, p53, E2F1), and 
modulation of the chromatin remodeling pathways (Tlk1/2).  
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Figure 17. Chk1 and Chk2 as mediators of the checkpoint-signaling network. In red unique Chk2 
substrates, in green unique Chk1 substrates, in blue – overlapping ones. The known target sites of Chk1 
(green), Chk2 (red), and both Chk1 and Chk2 (blue) on the individual substrates are shown. Some of the 
Chk1/Chk2 downstream effectors are classified as protooncogenes (PO) or tumor suppressors (TS), as 
indicated (by Bartek J. and Lukas J., 2003). 
 
 
2.6.4.2. G1 checkpoint  
 
To prevent entry into S-phase with damaged DNA, cells traversing G1 activate the 
checkpoint transducing kinases ATM/ATR and Chk1/Chk2 which, in turn, target two 
critical effectors operating in distinct branches of the G1 checkpoint, the Cdc25 
phosphatase and the transcription factor p53 (Lukas J. et al, 2004).  
The phosphorylation of Cdc25A on multiple serine residues by Chk1 and Chk2 leads to its 
enhanced ubiquitination and degradation (Zhao H. et al, 2002), (Sorensen C.S. et al, 2003), 
by SCFβTRCP (described earlier), thereby preventing the Cdc25A-mediated activatory 
dephosphorylation of Cdk2 (Mailand N. et al, 2000). Such inhibition of Cdk2 blocks 
loading onto chromatin of Cdc45, a protein essential for recruitment of DNA polymerase α 
into assembled pre-replication complexes, thus preventing DNA synthesis (Falck J. et al, 
2002). The checkpoint pathway targeting Cdc25 A is implemented rapidly, operates 
independently on the p53 status and is relatively transient, capable of delaying cell cycle 
progression only for several hours (Mainland N. et al, 2000). On the other hand, the 
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complementary mechanism responsible for prolonged maintenance of the G1 cell cycle 
arrest in response to DNA damage, depends on p53. 
In contrast to Cdc25A, p53 phosphorylation is carried out not only by Chk1 and Chk2, 
phosphorylating p53 on threonine 18 and serine 20 (and possibly other residues), but also 
directly by the upstream checkpoint kinases ATM and ATR, particularly on serine 15. 
Additionally, the ubiquitin ligase Mdm2, responsible for p53 degradation is also targeted 
by ATM/ATR in response to DNA damage. The detailed mechanism of p53 involvement 
in the cell cycle arrest is described in chapter 2.6.5. Accumulation of p21, p53 target, 
sufficient for blocking G1/S promoting cyclins may require up to several hours, and this 
mechanism complements and eventually replaces the transient acute inhibition of Cdk2 
through the Cdc25A degradation pathway, thereby leading to a sustained, or sometimes 
permanent cell cycle blockade. Figure 18 shows schematically the order of events leading 
to G1/S arrest. 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. G1/S checkpoint.  
(after Nyberg K.A. et el, 2002) 
(description in the text) 
 
 
 
2.6.4.3. Intra S-phase checkpoint 
 
The S-phase checkpoint activated by genotoxic insults causes only transient, reversible 
delay in cell cycle progression, mainly by inhibition of new replicon initiation, thereby 
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resulting in a slow down of DNA replication. Thus, unlike the G1 and G2/M checkpoints, 
the intra-S-phase response to DNA damage lack sustained cell cycle arrest.  
It seems that there are at least two parallel pathways in this checkpoint to slow down 
ongoing DNA synthesis, both of them controlled by the ATM/ATR machinery. One of 
these effector mechanisms operates via the Cdc25A cascade, described in the previous 
chapter. The other pathway reflects the impact of ATM-mediated phosphorylation of 
NBS1 on several sites, in particular serine 343 (Siloh Y., 2003) as well as serine 957 and 
966 of the cohesin protein, SMC1 (Kim S.T. et al, 2002), (Kitagawa R. et al, 2004). Some 
role of proteins BRCA1 and FANCD2 (Fanconi anaemia, complementation group 2) in 
mediating this action has been reported (Taniguchi T. et al, 2002), (Nakanishi K. et al, 
2002).  
Most recently, the S-phase kinases Cdc7/Dbf4 (Costanzo V. et al, 2003) and the Tlk1 
(Groth A. et al, 2003), (Krause D.R. et al, 2003) have also turned out to be targeted by the 
checkpoint kinase ATM/ATR and Chk1, although the exact mechanism and the biological 
significance of these events remain unknown.  
Apart from the inhibition of replication-origin firing, another critical function provided by 
S-phase checkpoint is to protect the integrity of the stalled replication forks. Such 
maintenance of fork stability, achieved through yet unknown mechanism, helps prevent the 
conversion of primary lesions into DNA breaks and facilitates the subsequent recovery of 
DNA replication (Bartek J. et al, 2004). 
 
 
2.6.4.4. G2 (G2/M) checkpoint 
 
The G2 checkpoint prevents cells form entering mitosis when DNA is damaged, either as a 
result of damaged experienced during G2 or when cells progressed into G2 with some 
unrepaired damage inflicted during previous S or G1 phases. G2 accumulation may also 
result from so-called DNA-replication checkpoint or S/M checkpoint that may sense some 
of the persistent lesions from the previous S-phase as being inappropriately or not fully 
replicated DNA. 
The critical target of the G2 checkpoint is the mitosis-promoting activity of the Cyclin 
B/Cdk1 kinase. Upon DNA damage Cyclin B/Cdk1 activation is inhibited by ATM/ATR 
and Chk1/Chk2-mediated sub-cellular sequestration as well as degradation and inhibition 
of the Cdc25 family of phosphatases that normally activate Cdk1 at the G2/M boundary 
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(Mailand N. et al, 2002), (Donzelli M. and Draetta G.F., 2003). Lately, it turned out that all 
three members of the Cdc25 family of phosphatases Cdc25A, Cdc25B and Cdc25C 
cooperate as positive regulators of Cyclin B/Cdk1 in unperturbed cell cycle. In response to 
DNA damage or incompletely replicated DNA, Ccd25A becomes degraded in G2, most 
likely via the same mechanism, that has been described above for the G1 and S-phase 
checkpoints (Xiao Z. et al, 2003). The Cdc25C phosphatase activity is instead blocked by 
its binding to 14-3-3 protein, a process induced by phosphorylation of Cdc25C on serine 
216 by kinases Chk1 and Chk2. The role of Cdc25B in G2 checkpoint has been connected 
with its phosphorylation at serine 309 by MAP kinase p38, which also induces binding to 
14-3-3 (Bulavin D.V. et al, 2001).  
Another level of complexity is added by the fact that other upstream regulators of Cdc25C 
and/or Cyclin B/Cdk1, such as the Polo like kinases, Plk1 and Plk3, seem to be targeted by 
DNA damage-induced mechanism. Scheme of G2 checkpoint is presented in Figure 19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. The G2/M checkpoint.  
(after Nyberg K.A. et el, 2002) (description in the text) 
 
 
One mechanism that contributes to long-term silencing of Cyclin B/Cdk1 is through p53 
pathway, described in the next chapter. On the other hand, many cell types lacking p53 still 
tend to accumulate in G2 after DNA damage, indicating that additional mechanisms, such 
 48
Introduction 
as the BRCA1-stimulated expression of p21 and GADD45 (Nyberg K.A. et al, 2002) may 
cooperate with the p53 cascade in regulating the delayed, sustained G2-arrest. 
 
 
2.6.5. p53 as a target of multiple checkpoint pathways 
 
The p53 tumor suppressor belongs to a small family of related proteins, that include two 
other members: p63 and p73 (Vousden K.H. and Lu X., 2002). Although structurally and 
functionally related, p63 and p73 have roles in normal development, whereas p53 seems to 
have evolved in higher organisms to prevent tumor development. Several responses can be 
provoked by p53, including cell cycle arrest, apoptosis, senescence, cell differentiation and 
angiogenesis (Sionov R.V. and Haupt Y., 1999).  
 
p53 plays a role in regulation various checkpoints during the cell cycle. The induction of 
p21WAF/Cip1 is responsible for G1 arrest, while the induction of 14-3-3σ, and to some extent 
that of GADD45 gene, mediate the G2 arrest. These checkpoints prevent the cell with 
damaged DNA from undergoing cell cycle progression (replication or mitosis, 
respectively). 
 
 
 
Figure 20. Induction of growth arrest by p53. Activation of p53 induces the transcription of target genes 
involved in cell cycle regulation. P21 is central for the induction of G1 arrest/senescence and replication 
arrest. GADD45 and 14-3-3σ promote G2 arrest through separate pathways. The parallel contribution of 
ATM is also included. (after Sionov R.V. and Haupt Y., 1999). 
 49
Introduction 
p21 mediates p53-dependent G1 arrest by inhibiting the activity of Cdks though its N-
terminal domain, leading to failure of Rb phosphorylation (as described in chapter 2.1.1.1). 
In addition interaction of p21 C-terminal domain with PCNA prevents activation of DNA 
polymerase δ, what leads to replication arrest. 
p53 can also contribute to block of the cell cycle independently of p21. By binding to 
Cyclin H and p36MAT1, p53 inhibits CAK, thereby preventing the activation of 
Cdk2/Cyclin A and blocking the G1/S transition. 
 
In addition, p53 was also shown to efficiently induce G2 arrest. The p53-induced gene 
product - 14-3-3σ sequesters the phosphorylated form of cdc25C, thereby preventing 
G2/M transition. In addition, another p53 target – GADD45 disrupts the CyclinB/Cdk1 
complex, probably via interaction with Cdk1, leading to inhibition of kinase activity and 
arrest at G2/M. Although G2 arrest can occur in the absence of p21 or p53, both proteins 
are essential for sustaining the G2 arrest after DNA damage (Bunz F. et al, 1998). 
 
The p53 protein has a very short half-life in normal condition, however exposure of cells to 
DNA damage leads to rapid accumulation of the protein. The mechanism of p53 
stabilization involves release of the p53 binding protein Mdm2 (Murine double minute 2), 
a proto-oncogene displaying E3 ligase activity and responsible for ubiquitinylation-
dependent p53 degradation. In an unperturbed cell cycle Mdm2 binds to p53 within its 
transactivation domain, blocks its transcriptional activity, and abrogates p53 ability to stop 
the cell cycle and induce apoptosis. Since the Mdm2 gene is direct target of p53, a negative 
autoregulatory feedback loop exists between those two proteins.  
It was known that DNA damage destabilizes Mdm2 by mechanism involving damage-
activated kinases and Mdm2 auto-ubiquitination, thereby preventing p53 degradation and 
stabilizing it (Stommel J.M. and Wahl G.M., 2004). 
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3. AURORA A KINASE 
 
3.1. Aurora kinase family  
 
Aurora is the name given to a family of serine/threonine protein kinases that regulate many 
aspects of cell division. They are known to be involved in the control of centrosome and 
nuclear cycles, and have essential functions in mitotic processes, such as chromosome 
condensation, spindle dynamics, kinetochore-microtuble interactions, chromosome 
orientation and establishment of the metaphase plate as well as the proper completion of 
cytokinesis (Carmena M. and Earnshaw W.C., 2003).  
The original aurora allele was identified in a screen for Drosophila melanogaster mutants 
defective in spindle-pole behavior, and was named after the phenomenon of the night sky 
in the polar regions (Glover D.M. et al, 1995) The first member of the family was however 
identified in Xenopus (named Eg2) (Paris J. and Philippe M., 1990). We know now that 
there are three types of Aurora in mammals (Aurora A, Aurora B and Aurora C), two in 
frogs, Drosophila and C.elegans (the A- and B-types), and a single one in budding (Ipl1) 
and fission (Ark1) yeast which seem to be most similar to B-type in function.  
 
Human Auroras A-C are kinases of a size ranging from 309 to 403 amino acid residues that 
exhibit a relatively high sequence divergence between species. As shown in Figure 21 they 
show similar domain organization: a N-terminal domain of 39-129 residues in length, a 
protein kinase domain and a short C-terminal domain of 15-20 residues. The N-terminal 
domain displays relatively low sequence conservation, within members of the family and 
this reflects on the selectivity of protein-protein interaction. 
The catalytic domain, on the other hand, is more conserved. The C-terminal domain of 
Aurora B shares 53% and 73% sequence similarity to human Auroras A and C, 
respectively. The comparison of the crystal structure of human Aurora A against the 
predicted structure of Aurora B and C also supports the thesis that vertebrate Aurora B and 
C are closely related paralogs (Brown J.K. et al, 2004). 
The alignment of Aurora A and B pointed to the presence of a distantly conserved KEN 
motif, spanning 11-18 residues, which acts as Cdh1-dependent APC/C recognition signal.  
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Figure 21. Domain organization of Aurora kinases A–C. As shown here, Aurora kinases present three 
domains: The N- and the C-terminal domains contain most of the Aurora's regulatory motifs, while the 
central region contains the catalytic domain. In addition to the kinase activity, this central domain also 
presents regulatory motifs, as the crystal structure of the Aurora A-TPX2 complex has shown (after Bolans-
Garcia V.M., 2005) 
 
 
Surprisingly, given this level of similarity, the three mammalian Aurora kinases have very 
distinct localizations and functions. 
Aurora A kinase is associated with the centrosome from the time of centrosome 
duplication to mitotic exit and with regions of microtubules proximal to centrosomes in 
mitosis. Aurora B forms a complex with two proteins, inner centromere protein (INCENP) 
and survivin and behaves like a chromosomal “passenger” protein. Less is known about 
Aurora C kinase, which is specifically expressed at high levels in the testis and shows 
centrosomal localization from anaphase to telophase. 
Despite the high conservation of their catalytic domains, which would indicate similar site 
specificity, Aurora kinases differ in the substrate specificity. This is likely explained by the 
different sub-cellular localization of Aurora family members and by the interaction with 
different sets of partners. A brief overview of specific Auroras’ substrates, their cellular 
localization and function is presented in Table 3. 
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Substrate  Cell localization Effect of substrates-Aurora interaction 
 
AurA PP1    mitotic spindle   spindle assembly 
p53    centrosome   cytokinesis     
Cdh-1       centrosome maturation and separation 
TPX-2      
RasGAP       
Ajuba   
 
AurB histone H3   centrosome   chromosome alignment and segregation 
INCENP   central spindles  cytokinesis 
CENP-A  chromosome arms microtubule dynamics 
desmin 
Rec-8 
vimentin;  
MCAK;  
survivin   
 
AurC Aurora B   central spindles  role in spermatogenesis 
INCENP. chromosome arms? possible role in regulation of chromosome  
segregation and cytokinesis 
 
 
Table 3. Human Aurora kinases A–C exhibit differential substrate affinity, subcell localization and 
associated activities (after Bolans-Garcia V.M., 2005) 
 
 
I will now describe each of the Aurora family members in more details, taking the 
“alphabetically-reverse” order, which corresponds more logically to the aim of my study.  
 
 
3.1.1. Aurora C 
 
Aurora C was first identified in a screen for kinases expressed in mouse sperm and eggs 
(Tseng T.C. et al, 1998) and for long time was believed to function only in testis. Only 
later Aurora C over-expression was also demonstrated in certain cancer cell lines (Kimura 
M. et al, 1999). The Aurora C gene is localized to 19q13.43 region, which is often 
translocated or deleted in certain cancer tissues. Its protein level seems to be cell cycle 
regulated with low expression in interphase and peak levels at G2 and mitosis. Aurora C 
localizes to centrosomes in anaphase and persists there until cytokinesis, suggesting that it 
may have a role during late stages of M-phase (Kimura M. et al, 1999). Little is known 
about regulation of  protein and kinase activity, with the exception of a report an 
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apparently negative phosphorylation site (T171), which is recognized and phosphorylated  
in vitro by protein kinase A (PKA) (Chen S.S. et al, 2002). Aurora C was found to be 
activated by INCENP (inner centromere protein), and over-expression of those two 
proteins was shown to increase phosphorylation of histone H3, an event that is rather under 
the control of Aurora B (see chapter 3.1.2) (Li X. et al, 2004), (Sasai K. et al, 2004).  
 
 
3.1.2. Aurora B 
 
Human Aurora B was identified in a PCR screening for kinases overexpressed in colorectal 
cancers (Bischoff J.R. et al, 1998) and it was later shown to be involved in several 
important processes during mitosis.  
Aurora B is localized along the length of chromosomes at prophase, whereas it relocates at 
the inner centromere regions near the kinetochores during prometaphase and metaphase. At 
anaphase it is present at the spindle midzone and finally in the midbody at the end of 
cytokinesis (Adams R.R. et al, 2001).  
Aurora B protein and activity levels are tightly regulated during transition through the cell 
cycle, with a peak of protein expression at the G2/M transition and the maximal activity at 
mitosis. The activity of Aurora B is regulated based on two independent mechanisms: 
phosphorylation and protein-protein interaction. It has been shown that Aurora B kinase 
activity dramatically increases upon treatment with the phosphatase inhibitor, okadaic acid, 
yet the kinase responsible for phosphorylation of Aurora B has not been found (Sugiyama 
K. et al, 2002). The same study has also shown that Aurora B physically associates with 
protein serine/threonine phosphatase type 1 (PP1) and PP2A that likely contribute to 
determine the balance between positive and negative inputs affecting Aurora B activity. 
Moreover, Aurora B activity is positively regulated through the association INCENP and 
survivin. The former is a microtubule-binding protein that is targeted to the chromosomes 
and centromeres through its non-conserved N-terminal region. INCENP contains a motif 
(IN-box) in its highly conserved C-terminal region that is responsible for binding to 
Aurora. (Honda R. et al, 2003). Aurora B-dependent phosphorylation of a site contained 
the IN-box functions in a positive feedback loop to enhance Aurora activity (Bishop J.D 
and Schumacher J.M., 2002). Survivin is a small protein that contains a BIR (baculovirus 
inhibitor of apoptosis (IAP) repeat) domain and a Zinc-finger motif typical for IAP 
proteins. Survivin was shown to enhance Aurora B kinase activity in vitro (Bolton M.A. et 
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al. 2002), and treatment with siRNA against survivin resulted in decrease of Aurora B 
activity and mislocalization of the kinase (Chen J. et al, 2003). 
Aurora B kinase is responsible for phosphorylation of histone H3 on serine 10 (Hsu J.Y. et 
al, 2000), (Giet R. and Glover D.M., 2001), (Crosio C. et al, 2002) a post-translational 
modification that is associated with chromatin condensation. It was also found to be 
responsible for phosphorylation of H3 at serine 28 from prophase to metaphase (Goto H. et 
al, 2002). Other specific substrates of Aurora B are myosine II regulatory light chain 
(Murata-Hori M. et al, 2000), vimentin (Goto H. et al, 2003), desmin and glial fibrillary 
acidic protein (GFAP) (Kawajiri A. et al, 2003), all of them involved in late stages of 
cytokinesis. Also MgcRacGAP, a known activator of Rho A important for actin 
polymerization and completion of cytokinesis, was found to be phosphorylated by Aurora 
B (Jantsch-Plunger V. et al, 2000). Some role in meiosis, namely phosphorylation of Rec8, 
a meiotic-specific subunit of the cohesin complex was also attributed to Aurora B (Rogers 
E. et al, 2002). 
The role of Aurora B in DNA damage response has been postulated recently. Aurora B was 
shown to physically and specifically associate with the BRCT (BRCA-1 C-terminal) 
domain of PARP-1 (poly(ADP-ribose) polymerase 1), a protein involved in DNA damage 
detection and repair. In response to DNA damage Aurora B becomes highly poly(ADP-
ribosyl)ated, an event that leads to the inhibition of its kinase activity and hence to 
reduction of serine 10 phosphorylation of histone H3 (Monaco L. et al, 2005) 
 
 
3.2. Aurora A 
 
The gene encoding Aurora A is located on chromosome 20, in a region often amplified in 
human tumors (20q13). Overexpression of Aurora A protein has been reported in several 
cancers, such as breast (Royce M.E. et al, 2003), colorectal (Bischoff J.R. et al, 1998), 
bladder (Tseng Y-S. et al, 2005), thyroid (Ulisse S. et al, 2006), NHL (Non-Hodgkin’s 
Lymphoma) (Yakushijin Y. et al, 2004) and gastric cancer (Yamada K.K. et al, 2004) in a 
manner that is both dependent and independent from gene amplification.  
The human gene exhibits significant homology with the previously cloned prototypic yeast 
Ipl1 (40% of identity) and Drosophila aurora (48% of identity) protein serine/threonine 
kinase-encoding genes. The translated human Aurora A protein consists of 403 amino 
acids and has a molecular weight of 46 kilodaltons (Sens S. et al, 1997). 
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Aurora A has an important regulatory role in spindle formation, and therefore is essential 
for accurate chromosome segregation. Depending on the organism and on differences in 
their cell cycle, Aurora A mutations interfere with recruitment of γ-tubulin ring complex 
and other proteins during centrosome maturation, formation of a bipolar spindle, 
maintenance of the bipolar spindle, and chromosome segregation (Crane R. et al, 2003). 
 
 
3.2.1. AurA regulation  
 
Aurora A level as well as its activity is tightly cell cycle regulated, being low at G1 and S, 
increasing at G2, reaching the maximum at mitosis and then being rapidly degraded 
(Bischoff J.R. et al, 1998), (Krystyniak A et al, 2006).  
 
 
3.2.1.1. Phosphorylation  
 
Similarly to other Aurora family members Aurora A activity is regulated by 
phosphorylation. The phosphorylation of a conserved residue, threonine 288, localized in 
the activation loop of the catalytic domain of the kinase, results in a significant increase of 
Aurora A kinase activity. Threonine 288 can be phosphorylated in vitro by protein kinase 
A (PKA) (Walter A.O. et al, 2000). However a role for PKA in vivo is questionable since 
PKA activity is low when cells approach mitosis and Aurora A can autophosphorylate at a 
number of sites, including threonine 288 and thereby autoactivate (Ferrari S. et al, 2005). 
Two other phosphorylation sites have been found by mass spectroscopy at mitosis in 
Xenopus Aurora A, namely serine 53 and serine 349 (S51 and S342 in the human Aurora 
A) (Littlepage L.E. et al, 2002). S53 is part of the A-box, a highly conserved motif 
required for destruction of Aurora A at mitosis, whereas S349 is N-terminal to a protein 
phosphatase 1 (PP1)-binding motif. Mutations of serine 53 to both alanine and aspartic 
acid had no significant effect on kinase activity. However, the Asp53 was shown to be 
more stable than wild type, suggesting that phosphorylation at this site might regulate 
Aurora A destruction during mitosis (Littlepage L.E. et al, 2002). Mutation of serine 349 to 
alanine slightly reduced Aurora A activity, whereas mutation of this site to aspartic acid 
completely abolished it. The authors suggested that either phosphorylation of serine 342 is 
inhibitory, or that it is somehow critical for the conformation of Aurora A in some other 
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way. Our data indicated that mutation of S342 to alanine in human Aurora A resulted in an 
isoform displaying the same activity as wild type. Therefore, given its close proximity to 
the PP1 binding motif, it is more likely that phosphorylation at S342 is involved in the 
control of the interaction of Aurora A with critical regulators (Krystyniak A. et al, 
manuscript in preparation).  
 
 
3.2.1.2. Binding partners 
 
3.2.1.2.1. Activation of Aurora A by TPX2 
 
TPX2 (Target Protein for Xenopus kinesin-like protein 2) is a microtubule-associated 
protein, which is required for induction of spindle assembly (Gruss O.J. et al, 2002). TPX2 
appears to be tightly regulated during the cell cycle, with protein level peaking at mitosis 
and declining sharply during mitotic exit (Steward S. and Fang G., 2005). TPX2 is a key 
target of the Ran-GTP pathway. It was found to be sequestered through its association with 
importin β in the absence of Ran-GTP, whereas during mitosis, Ran-GTP, that is generated 
by RCC1 around chromosomes disrupts the TPX2 - importin β complex, thus releasing 
active TPX2 to initiate bipolar spindle assembly (Gruss O.J. at al, 2002). Similarly, human 
TPX2 is involved in spindle formation, spindle pole organization and centrosome integrity, 
as shown in experiments with siRNA (Garret S. et al, 2002).  
It has been shown that N-terminus of TPX2 binds to C-terminal catalytic domain of Aurora 
A, and targets it to the spindle apparatus (Kufer T.A. et al, 2002). Upon siRNA-mediated 
depletion of TPX2, the association of Aurora A with spindle microtubules was abolished, 
although its association with spindle poles was not affected. Depletion of Aurora A, on the 
other hand, did not result in mislocalization of TPX2. Further studies have shown that in 
vitro-dephosphorylated Aurora A, becomes phosphorylated and activated by TPX2 in an 
ATP dependent manner (Eyers P.A. et al, 2003). Increased phosphorylation and activation 
of Aurora A requires its own kinase activity, suggesting that TPX2 stimulates 
autophosphorylation and autoactivation of the enzyme. The molecular mechanism of this 
activation was found by determining the crystal structure of phosphorylated Aurora A, 
both with and without a 43-residue domain of TPX2. The data indicated that such domain 
fully supported kinase activation and protected the T-loop site from dephosphorylation. In 
the absence of TPX2, the Aurora A activation segment was shown to be in an inactive 
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conformation, with the crucial phosphothreonine 288 exposed and therefore accessible for 
dephosphorylation. Mechanistically, binding of TPX2 pulls on the activation segment, 
swinging the phosphothreonine into a buried position and locking the active conformation, 
without any global conformational changes in the kinase (Bayliss R. et al, 2003). 
Figure 22 presents schematically activation of Aurora A by TPX2.  
 
 
 
Figure 22. Activation of Aurora A by 
TPX2 binding. The Microtubule-
Associated Protein TPX2 Is Released 
from Its Complex with Importin 
through the Activity of Ran-GTP. The 
released molecule makes contact with 
two regions in the N-terminal lobe of 
autophosphorylated Aurora A kinase. 
One of these interactions pulls on a 
lever arm structure to compact the 
activation domain and bury the 
phosphate group on Thr288 and so 
protect it from hydrolysis by PP1 (after 
Glover D.M., 2003) 
 
 
Detailed studies carried out in Xenopus revealed the role of G205 as a key site for 
regulation of TPX2-mediated activation of Aurora A (Bayliss R. et al, 2004). Mutation of 
this site to N, the equivalent residue in Aurora B, had no effect on autophosphorylation of 
the T-loop threonine 295 (analog of 288 in human), but instead led to about ten-fold loss of 
specific activity. Likewise, the opposite mutation in Aurora B (N to G) caused 350-fold 
increase in activity. G205N Aurora A was found still to be activated by TPX2, but 
protection of threonine 295 from dephosphorylation by PP1 was abolished. Structural 
analysis suggested that the presence of G in position 205 results in the movement of the N-
terminal domain glycine-rich loop closer to the ATP binding site of the enzyme and also 
moves the C-helix slightly closer to the activation loop, which would suggest that 
phosphorylation in the activation loop alone is not sufficient for enzyme activation (Eyers 
P.A. et al, 2005). 
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3.2.1.2.2. Inhibition of Aurora A by PP1 
 
Aurora A has two PP1-binding motifs, one that includes the catalytic lysine residue 
(K169VLF) and a second, immediately adjacent to serine 342 (K343VEF) (Katayama H. et 
al, 2001). Binding of PP1 to Aurora A is cell cycle regulated and peaks at mitosis. 
Activated Aurora A phosphorylates PP1 and inhibits its activity in vitro as well as in vivo, 
although evidence for direct phosphorylation in vivo is lacking. On the other hand, PP1 
also was shown to dephosphorylate active Aurora A in vitro, and thereby abolish its 
activity. The postulated mechanism for the Aurora A – PP1 interaction envisages 
phosphorylation of Aurora A at serine 342 as a mean to decrease binding of PP1 to the 
K343VEF motif, thus preventing dephosphorylation of threonine 288 and possibly other 
sites required for Aurora A activity (Littlepage L.E. et al, 2002) (see also Results). 
It has also been shown that human PP1 inhibitor 2 (I-2) directly and specifically stimulates 
recombinant Aurora A activity in vitro, in a manner that is independent of PP1inhibition. 
The C-terminal region of I-2, which is distinct from the primary PP1 binding site, was 
found to be required for kinase activation, suggesting that two separate regions in I-2 serve 
two independent functions in Aurora A regulation: one as a PP1 inhibitor and the other as a 
direct kinase activator (Satinover D.L. et al, 2004).  
 
 
3.2.1.2.3. Other binding partners influencing Aurora A activity 
 
Screening experiments done in yeast led to identification of another negative regulator of 
Aurora A, named AIP (Aurora A kinase Interacting Protein) (Kiat L.S. et al, 2002). AIP is 
a ubiquitously expressed nuclear protein shown to specifically interact with human Aurora 
A in vivo. Ectopic expression of both proteins resulted in the down-regulation of Aurora A 
protein level and this down-regulation was due to destabilization of the protein through a 
proteasome-dependent degradation pathway. On the other hand a non-interacting mutant of 
AIP did not have any effect on Aurora A, showing that the interaction between Aurora A 
and AIP is important for Aurora A degradation.  
A two-hybrid screen identified the LIM protein Ajuba, homolog of a LIM domain-
containing protein that promotes meiotic maturation of Xenopus oocytes, as an Aurora A 
binding partner (Hirota T. et al, 2003). Ajuba and Aurora A interact in mitotic cells and 
become phosphorylated during this interaction. In vitro kinase assay with histone H3 as a 
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substrate showed that Ajuba stimulates Aurora A activity and does so by stimulating 
autophosphorylation at threonine 288.  
Similar type of Aurora A stimulation through binding-induced autophosphorylation - was 
reported for HEF1, a scaffolding protein, present in spindle asters at mitosis and involved 
in integrin-dependent attachment signaling at focal adhesions (Pugacheva E.N. and 
Golemis E.A., 2005). 
GSK-3 (glycogen synthase kinase 3) was shown to regulate the activity of Xenopus Aurora 
A (Sarkissian M. et al, 2004). Both proteins were found to interact in vivo and GSK-3 was 
shown to phosphorylate Aurora A at serine 290/291 in vitro. This, in turn was shown to 
promote autophosphorylation of Aurora A at serine 349 (human 342), resulting in a 
reduction of the kinase activity (see also chapter 3.2.1.1). 
The list closes with the only one kinase shown so far to be able to phosphorylate Aurora A 
in vivo – PAK1 (Zhao Z-S. et al, 2005). Active PAK1 was shown to bind to and 
phosphorylate Aurora A both at threonine 288 and serine 342, promoting the activity of the 
latter. Thus, in contrast to Ajuba or TPX2, which can only bind to active Aurora A and 
preserve its active state, PAK1 efficiently binds to inactive Aurora A and induces its 
activation.  
 
 
3.2.1.2.4. Inhibition of Aurora A by p53 
 
Using a transactivation-defective mutant as a bait, human p53 protein was shown to 
directly bind to Aurora A, in a yeast two-hybrid screen (Chen S-S. et al, 2002). The 
evidence obtained in this study was confirmed in vivo by a series of co-
immunoprecipitations and GST pull-down assays in which the region of interaction 
(residues 1 to 318 of p53) was characterized. Interestingly, the N-terminal region of Aurora 
A containing the Aurora-box, which has been proposed to be a motif for protein-protein 
interaction (Giet R. and Prigent C., 1999), was sufficient for interaction with p53. The p53-
Aurora A interaction resulted in suppression of Aurora A kinase activity in vitro. The same 
transcriptionally inactive p53 can suppress Aurora A-induced centrosome amplification 
and cellular transformation in vivo, further supporting the idea that p53 negatively 
regulates Aurora A by a direct protein-protein interaction rather than in a transactivation-
dependent manner. By contrast, p53 does not suppress transformation induced by Aurora A 
lacking the N-terminus.  
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3.2.1.3. Aurora A chemical inhibitors 
 
Aurora kinases are important factors in the control of chromosomal stability and, thus, 
posses a potential importance in cancer. This thinking was confirmed by the finding that 
both Aurora A and B are frequently overexpressed in many cancer cells. This has led to the 
idea that inhibiting the activity of Aurora kinases may have therapeutic utility in cancer. A 
number of compounds belonging to various structural families have been reported to 
possess inhibitory activity against Aurora A and to display sufficient selectivity when 
tested on other protein kinases to allow undertaking both in vitro and in vivo studies.  
ZM447439 (Ditchfield C. et al, 2003), a quinazoline derivative, is an ATP-competitive 
inhibitor that, in in vitro kinase assays, inhibits Aurora A (and B) with IC50 values of 
approximately 0,1 µM. This inhibition is relatively specific, since ZM447439 shows no 
inhibition (IC50 higher then 10 µM) of a range of kinases including Cdk1 and Plk1.  
VX-680 (Harrington E.A., et al, 2004), cyclopropane carboxylic acid {4-[4-(4-methyl-
piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-
amide, a small-molecule inhibitor targeting the ATP-binding site, is a potent inhibitor of all 
three Aurora kinases, with apparent inhibition constant values of 0,6, 18 and 4,6 nM for 
Aurora A, Aurora B and Aurora C, respectively. VX-680 shows greater than 100-fold 
selectivity for the Aurora A kinase over 55 other kinases tested, with the only exception for 
Fms-related tyrosine kinase 3 (FLT-3), the IC50 for which is 30 nM.  
JNJ-7706621 (Emanuel S. et al, 2005), a (1,2,4)triazole-3,5-diamine dual Cdk and Aurora 
inhibitor is able to effectively block cell cycle progression. JNJ-7706621 shows a potent 
inhibition of several cyclin-dependent kinases and Aurora kinases and selectively blocks 
proliferation of tumor cells of various origins, independently on p53 and Rb status.  
 
Further chemical modification of known inhibitors (like ZM447439) led to a panel of more 
selective and potent inhibitors with potential clinical use (Heron N.M, et al, 2006), (Jung 
F.H., et al, 2006).  
 
 
3.2.1.4. Degradation 
 
 61
Introduction 
Destruction of Aurora A is dependent on a specialized ubiquitin ligase APC/C-ubiquitin-
proteasome pathway (Honda K. et al, 2000). Association of two distinct WD40 repeat 
proteins, Cdc20 and Cdh1, respectively, sequentially activates APC/C (see chapter 2.3.2). 
It has been reported that Aurora A degradation is dependent on Cdh1, not on Cdc20 
(Taguchi S. et al, 2002), although Cdc20 was found to be associated with Aurora A 
(Farruggio D.C., 1999). Cdh1, which is also required for the destruction of several mitotic 
regulatory proteins during late mitosis, binds to two well-characterized APC/C recognition 
signals: the destruction box and the three-residue KEN sequence. Both signals are highly 
conserved in Aurora A and Aurora B, although it was shown that Cdh1-dependent 
degradation of Aurora A does not require the KEN sequence. Determinant for Aurora A 
degradation are the C-terminal destruction box (Arlot-Bonnemains Y. et al, 2001) and a 
sequence in the non-catalytic N-terminal domain, the A box (Littlepage L.E. and 
Ruderman J.V., 2002) (Figure 23). 
The A-box is conserved in vertebrate Aurora A, but not in other members of the Aurora 
family. Serine 53 is phosphorylated during M phase and is part of an A-box. Mutation of 
this residue to aspartic acid, which can mimic the effect of phosphorylation, completely 
blocks Cdh1-dependent destruction of Aurora A. This suggests that dephosphorylation of 
serine 53 during mitotic exit could control the timing of Aurora A destruction by 
facilitating recognition of both the A-box and the D-box by Cdh1-activated APC/C (Crane 
R., et al, 2004) (see also chapter 3.2.1.1).  
 
 
 
Figure 23. Schematic of 
potential destruction signals 
and catalytic residues in 
human Aur-A. The sequence 
alignment compares the A box 
in human (h) and Xenopus (x) 
Aur-A with the corresponding 
region in Aur-B. Residues 
conserved with human Aur-A 
are shaded. (after Crane R. et 
al, 2004) 
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3.2.2. AurA substrates and targets 
 
In addition to the previously described Aurora A interacting partners (TPX2, PP1, Ajuba), 
a variety of Aurora A substrates has been identified. I will now describe some of those, that 
are relevant to Aurora A physiological function and also its potential oncogenic targets.  
 
A two-hybrid screen identified the kinetochore component CENP-A as a protein that 
interacts with Aurora A (Kunitoku N. et al, 2003). Aurora A was shown to phosphorylate 
CENP-A in vitro on serine 7, a residue that is also phosphorylated by Aurora B. Further 
analysis showed that Aurora A and Aurora B phosphorylate serine 7 in sequential manner 
and that Aurora A phosphorylation is required for enrichment of Aurora B at inner 
centrosomes. Mitotic cells in which this phosphorylation was prevented, exhibited a 
substantial proportion of misaligned chromosomes as a result of a defect in the ability of 
kinetochores to attach to microtubules. Phosphorylation of CENP-A by Aurora A in 
prophase nuclei is thus essential for kinetochore function in mitosis.  
 
TACC3 (Transforming Acidic Coiled Coil 3), a human homologue of the centrosomally 
associated protein D-TACC, is phosphorylated by Aurora A at serine 558 (Kinoshita K. et 
al, 2005). TACC3 enhances the number of microtubules emanating from mitotic 
centrosomes, and its targeting to centrosomes was shown to be regulated by Aurora A-
dependent phosphorylation. Another work done in Drosophila showed that D-TACC is 
phosphorylated on serine 863 exclusively at centrosomes during mitosis, and this reaction 
is carried out by Aurora A (Barros T.P. et al, 2005). Phosphorylation at serine 863 was 
postulated to play a role in D-TACC-mediated stabilization of microtubules at their minus 
ends.  
 
Another centrosomal target of Aurora A is Lats2, a serine/threonine kinase, member of 
Lats kinase family including the Drosophila tumor suppressor Lats/Warts. Lats2 was 
shown to be phosphorylated by Aurora A on serine 83 both in vitro and in vivo (Toji S. et 
al, 2004) as well as interact with it and co-localize at centrosomes. The inhibition of 
Aurora A-induced phosphorylation of Lats2 partially perturbed its centrosomal 
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localization, suggesting that phosphorylation of Lats2 on serine 83 by Aurora A plays a 
role in centrosomal localization of Lats2. 
 
It has been shown that BRCA1, the breast cancer tumor suppressor, localizes to the 
centrosomes and BRCA1 inactivation results in loss of G2/M checkpoint. Aurora A 
physically binds to BRCA1 in the region 1314-1863 of BRCA1, and phosphorylates it both 
in vivo and in vitro at serine 308 (Ouchi M. et al, 2004). Phosphorylation of serine 308 
increases in the early M phase, paralleling the increasing level and activity of Aurora A. 
On the other hand, elimination of Aurora A by siRNA resulted in reduced phosphorylation 
of BRCA1. Expression of the mutant of this phosphorylation site (S308N) in BRCA1-
deficient mouse embryo fibroblasts, decreased the number of cells in M phase to a degree 
similar to that observed when G2/M arrest was induced by DNA damage in cells 
expressing wild-type BRCA1, suggesting that phosphorylation of the latter by Aurora A 
plays a role in the G2/M transition of cell cycle.  
 
The Cdc25B phosphatase, an activator of cyclin-dependent kinase at mitosis, was found to 
be phosphorylated by Aurora A on serine 353, both in vitro and in vivo (Dutertre S. et al, 
2004). Phosphorylated Cdc25B was found to localize at the centrosomes from prophase to 
anaphase. This phopshorylation was proposed to participate in the regulation of the entry 
into mitosis and suggests a local function of Cdc25B as one of the starters of mitosis.  
 
The most proximal known substrate of Aurora A is CPEB, a sequence-specific RNA 
binding protein, that stimulates cytoplasmic polyadenylation and translational activation 
(Sarkissian M. et al, 2004). CPEB interacts with the cytoplasmic polyadenylation element 
(CPE), a cis-element present in the 3’ untranslated regions (UTRs) of several mRNAs, 
including those encoding mos and Cyclin B. The translation of mos is necessary for 
induction the MAP kinase cascade that indirectly activates Cyclin B-Cdk1. Aurora A 
phosphorylation of CPEB on serine 174 enhances the association of CPEB with CPSF 
(cleavage and polyadenylation specific factor), possibly helping to stabilize this complex 
on the AAUAAA hexanucleotide, a second cis-element essential for polyadenylation.  
 
HURP (hepatoma upregulating protein) was found as one of the best Aurora A-correlated 
genes, using the gene expression profiles of Aurora A as a template (Yu C-T.R. et al, 
2005). HURP is a cell cycle-regulated gene, highly expressed during G2/M phase, where it 
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localizes to the spindle fibers, and sharply declines in early to middle G1 phase. Elevated 
HURP expression is highly associated with HCC, colon and breast cancers, and urinary 
bladder transitional-cell carcinoma, suggesting a role of HURP in carcinogenesis. 
Subsequent examination by quantitative RT-PCR confirmed that Aurora A and HURP 
have similar expression patterns in HCC. Aurora A was shown to phosphorylate HURP in 
in vitro assays, and in vivo. This phosphorylation was proposed to modulate HURP 
function probably by altering its stability or its ability to interact with other proteins.  
 
And last, but not least, p53 has been proven to be a substrate of Aurora A (Katayama H. et 
al, 2004). Aurora A was shown to phosphorylate p53 at serine 315, which leads to p53 
ubiquitination by Mdm2 and eventually its proteolysis. p53 was not degraded in the 
presence of kinase-inactive Aurora A and silencing of Aurora A resulted in decreased 
phosphorylation of p53 at serine 315, greater stability of p53 and cell cycle arrest at G2/M. 
Those results have led to the conclusion that Aurora A kinase is a key regulator of p53 
pathway and that its overexpression leads to increased degradation of p53, causing down-
regulation of checkpoint-response pathways and facilitating oncogenic transformation of 
cells. Another phosphorylation site of p53 as target of Aurora A has also been found (Liu 
Q. et al, 2004). According to the authors, serine 315 in not a major site of Aurora A 
phosphorylation of p53, instead they found serine 215 to be phosphorylated with higher 
stoichiometry. This phosphorylation abrogates p53 DNA binding and transactivation 
activity as was shown by the inhibition of its downstream targets, such as p21 and PTEN. 
Moreover, the authors have shown that Aurora A-dependent inhibition was exclusively due 
to its serine’s 215 phosphorylation, and not due to phosphorylation of serine 315.  
 
 
3.2.3 Aurora A in checkpoint control and DNA damage 
 
Cells over-expressing Aurora A were shown to enter anaphase inappropriately, despite 
defective spindle formation and the persistence of Mad2 at the kinetochores, a fact that 
creates constant activation of the spindle assembly checkpoint (Anand S. et al, 2003). This 
effect was reversed by an inhibitory mutant of Bub1, linking the mitotic abnormalities 
provoked by Aurora A over-expression to spindle checkpoint activity.  
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The first study linking Aurora A with DNA damage response came out in 2002 (Marumoto 
T. et al, 2002). The authors showed that Aurora A is inactivated by DNA damage at the 
end of the G2 phase of the cell cycle and that over-expression of the protein abrogated G2 
checkpoint and led to premature entry into mitosis in Rat1 cells. This study had, however, 
a number of shortcomings that do not allowed the data to be accepted without criticism 
(see also Results, Chapter 1, Discussion) and that will be dealt with later on in this thesis.  
A second study, that was carried out in parallel with ours showed that upon DNA damage 
Cdc25B is not phosphorylated by Aurora A (see chapter 3.2.2) and Aurora A itself is not 
activated (Cazales M. et al, 2005). The Authors showed that ectopic expression of Aurora 
A resulted in bypass of the checkpoint and this was partially overcome by an 
unphosphorylable Cdc25B mutant, S353A. Finally, the Authors showed that bypass of the 
G2 checkpoint by the Chk1 kinase inhibitor UCN-01 resulted in the activation of Aurora A 
kinase and hence phosphorylation of Cdc25B on serine 353. 
 
Since the aim of my study was to elucidate the role of Aurora A in the DNA damage 
response for further information concerning the subject see Results. 
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AIM OF STUDY 
 
 
The faithful replication and segregation of chromosomes as part of the cell division cycle 
requires that topological changes be imposed upon cellular DNA. Interconversion of 
different topological forms of DNA is catalyzed by DNA topoisomerases, a family of 
enzymes classified according to their catalytic mechanism of action. Type I enzymes 
introduce transient single-stranded breaks into DNA, pass an intact single strand of DNA 
through the broken strand, and then re-ligate the break. Type II enzymes, in contrast, make 
transient double-stranded breaks into one segment of DNA and pass an intact duplex 
through the broken DNA, before resealing the break (reviewed by Watt P.M. and Hickson 
I.D., 1994). 
Topoisomerase II is required for the viability of all eukaryotic cells and plays important 
roles in DNA replication, recombination, transcription, chromosome segregation and the 
maintenance of the nuclear scaffold. In human and other mammalian cells, there are at 
least two forms (α and ß) of the topoisomerase II enzyme (Tsai-Pflugfelder, M. et al, 1988) 
(Jenkins, J.R. at al, 1992). Topoisomerase II catalyses a transient double-stranded break in 
the DNA helix, allowing the passing of a second double strand of DNA through the break, 
which is then re-ligated. Topoisomerase poisons acts by prolonging the lifetime of these 
open intermediate ‘cleavable complexes’ forming obstructions that eventually lead to DNA 
damage (Fortune, J.M. and Osheroff, N., 2000). DNA damage upon double-strand 
breakage is normally sensed by ATM or ATR kinase complexes. These kinases directly 
phosphorylate the checkpoint kinases Chk1 and Chk2 that, in turn, phosphorylate Cdc25 
family members causing their inactivation by nuclear exclusion or degradation. The DNA 
damage signal mediated via Chk1 and Chk2 also regulates Cyclin B/Cdk1, Wee1 and other 
proteins involved in the G2/M transition, changing their expression, phosphorylation and 
subcellular localization (see Introduction). 
 
Topoisomerase II is a specific target for several clinically important anti-tumour drugs 
such as anthracyclines, e.g. adriamycin and daunorubicin, epipodophyllotoxins, e.g. 
etoposide and teniposide, anthracenedione, e.g. mitoxantrone, and aminoacridines, e.g. m-
AMSA (reviewed by Andoh T. and Ishida R., 1998). These compounds exert cytotoxic 
effects by stabilizing covalent complexes between topoisomerase II and DNA, the so-
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called ‘cleavable complex’, thus generating DNA double-strand breaks. They are often 
referred to as topoisomerase II poisons, because they convert the enzyme to DNA-cleaving 
toxins in conjunction with the agents. The cell killing mechanism of these ‘classical’ 
topoisomerase II inhibitors is believed to be related to enzyme-mediated DNA cleavage, 
and the mechanism(s) by which DNA damage leads to cell death is still under intense 
investigation (see (Binaschi M. et al, 1995) and (Watt P.M. and Hickson I.D., 1994) for 
reviews). 
 
It has been recently discovered that kinases involved in proper spindle formation play 
important roles in the cellular response to DNA damage. The role of Nek-2 and Plk1 in 
both DNA damage checkpoint and cell cycle arrest has already been elucidated (as 
described in Introduction).  
Much less is known about the involvement of Aurora A in DNA damage response. 
Published data is incomplete and reports are conflicting – for example in case of the issue 
of the relationship between Aurora A and Cyclin B/Cdk1 one study placed Aurora A as 
dependent on Cyclin B/Cdk1 (Marumoto T. et al, 2002) whereas an other proposed an 
opposite view, claiming that Aurora A was required for promoting Cyclin B/Cdk1 
activation (Hirota T. et al, 2003). The latter scenario seemed to us more likely since Aurora 
A overexpression correlates with tumour formation and checkpoint abrogation (see 
Introduction).  
The lack of clear picture on the mechanism controlling Aurora A prompted us to 
investigate the role of Aurora A as possible effector in the cellular response to DNA 
damage.   
 
In my study I used etoposide (Figure 1) as an agent creating double-strand breaks in DNA.  
 
 
 
 
 
 
Figure 1. Etoposide 
4'-demethyl-epipodophyllotoxin, 4,6-O-
ethylidene-beta-D- glucopyranoside (8CI) 
(picture from Wikipedia 
http://en.wikipedia.org/wiki/Etoposide) 
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The reason for choosing etoposide, rather than ionizing radiation, was essentially technical 
(i.e. simplicity of administration and possibility to treat several sets of culture plates at 
once). On the other hand, I was able to get comparable results using either etoposide or IR,  
which allowed me to conclude that the response of Aurora A is specific to the presence of 
double-strand breaks, rather than being a stress response to the etoposide treatment.  
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Abstract 
 
Upon induction of DNA damage in form of double strand breaks several kinase 
pathways are activated leading to the cell cycle arrest. Among them Aurora A was 
found to be actively inactivated with corresponding lack of its degradation. Here, we 
provide evidence that inhibition of Aurora A kinase activity is dependent on its 
binding status to protein phosphatase 1 (PP1) and partially to TPX2. We demonstrate 
that upon etoposide treatment PP1 binding to Aurora A is diminished. Using mutants 
with point mutation in one of the sites responsible for PP1 binding (S342->A and 
S342->D) we show that phosphorylation at this residue plays a role in binding of PP1 
both in the normal conditions and upon induction of double strand breaks. Lack of 
S342 phosphorylation abrogates releasing of PP1 from Aurora A – PP1 complex upon 
DNA damage. Our previous study showed that the same mutation (S342A) prevents 
Aurora A from deactivation in response to damage.  
We also show that upon DNA damage TPX2 binding to Aurora A is highly impaired. 
On the other hand, the phosphorylation status of T288 – a T-loop site – does not 
change dramatically in the damage conditions. These findings indicate that inhibition 
of the kinase activity of Aurora A upon DNA damage is a complex process that 
requires orchestrated action of several factors and that S342 site plays there an 
important role.  
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Introduction 
 
 
One of the most important features to the maintenance of genome stability is the ability of 
cells to respond to DNA damage by slowing down or temporarily blocking the cell cycle, 
thus allowing damage to be repaired. This process, known as “DNA damage response” 
involves sensing of damage by a specialized set of proteins, transmission of this signal to 
repair proteins and at the same time delaying the onset of mitosis, a process that is also 
under control of a specialized protein network. Defects in the so-called cell cycle 
checkpoint pathways are associated with an array of phenotypes in mammals including 
cancer predisposition and neurodegeneration. 
The key components of mammalian DNA structure checkpoints' network can be divided 
into five categories, based on the position and general function in the network: (1) sensors 
– Rad9-Hus1-Rad1, so-called 9.1.1 complex, PCNA-like sliding clamp complex, the 
Rad17-RFC clamp loading complex and possibly the Mre11-Rad50-Nbs1 or MNR 
nuclease complex (Melo J. et al, 2002), (Petrini J.H. and Stracker T.H., 2003), (2) 
mediators – BRCA1, MDC1/NFBD1, 53BP1 and Claspin (Petrini J.H. and Stracker T.H., 
2003), (3) signal transduction kinases – kinases of the phosphatidylinositol 3-kinase 
(PI3K)-like family, ATM and ATR (Abraham R.T., 2001), (Siloh Y., 2003) (4) effector 
kinases – Chk1 and Chk2 (Bartek J. and Lucas J., 2003) and (5) effector proteins – a large 
and diverse group encompassing cell cycle regulators such as the Cdc25 phosphatase, 
various DNA repair proteins, transcription factors such as p53 and E2F, chromatin 
components and regulators such as histone H2AX and Tlk kinases, and others (Zhou B.B. 
and Elledge S.J., 2000), (Donzelli M. and Draetta G.F., 2003). 
Lately it has been also postulated that kinases involved in proper spindle formation play 
important roles in the cellular response to DNA damage, among them Plk1, Nek-2 and 
Aurora A.  
Aurora A is a protein kinase possessing an important regulatory role in spindle formation, 
and chromosome segregation. Its level and activity are cell cycle regulated with a peak of 
both at mitosis and rapid degradation shortly thereafter (Bischoff J.R. et al, 1998), 
(Krystyniak A et al, 2006). Overexpression of Aurora A protein was found in several 
cancers, such as breast (Royce M.E. et al, 2003), colorectal (Bischoff J.R. et al, 1998), 
bladder (Tseng Y-S. et al, 2005), thyroid (Ulisse S. et al, 2006), NHL (Non-Hodgkin’s 
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Lymphoma) (Yakushijin Y. et al, 2004) and gastric cancer (Yamada K.K. et al, 2004) in a 
manner that is both dependent and independent from gene amplification. 
Aurora A activity is regulated both by its phosphorylation and interaction with other 
proteins. Among the most influencing interactors, working antagonistically to one another, 
are TPX2 and PP1. In vitro-dephosphorylated Aurora A, becomes phosphorylated and 
activated by TPX2 in an ATP-dependent manner (Eyers P.A. et al, 2003), in a process that 
requires its own kinase activity. TPX2 therefore stimulates autophosphorylation and 
autoactivation of the enzyme by strictly mechanistic protection of the T-loop site from 
dephosphorylation by PP1 (Bayliss R. et al, 2003). Three phosphorylation sites have been 
found in mitotic Aurora A. Threonine 288, localized in the activation loop of the catalytic 
domain of the kinase is necessary for the kinase activity. Although this residue can be 
phosphorylated in vitro by protein kinase A (PKA) (Walter A.O. et al, 2000), a role for 
PKA in vivo is hardly possible, since PKA activity is low when cells approach mitosis. On 
the other hand, Aurora A was shown to be able to autophosphorylate at a number of sites, 
including Threonine 288 and thereby autoactivate (Ferrari S. et al, 2005). Two other 
phosphorylation sites have been found in Xenopus Aurora A, namely Serine 53 and Serine 
349 (S51 and S342 in the human Aurora A) (Littlepage L.E. et al, 2002). S53 is part of the 
A-box required for destruction of Aurora A at mitosis, whereas S349 is adjacent to one of 
the protein phosphatase 1 (PP1)-binding motifs. Mutations of Serine 53 to both Alanine 
and Aspartic acid had no significant effect on kinase activity. However, the Asp53 was 
shown to be more stable than wild-type, suggesting that phosphorylation at this site might 
regulate Aurora A destruction during mitosis (Littlepage L.E. et al, 2002). Mutation of 
Serine 349 to Alanine slightly reduced Aurora A activity, whereas mutation of this site to 
Aspartic acid completely abolished it. The Authors suggested that either phosphorylation 
of Serine 342 is inhibitory, or that it is critical for the regulation of Aurora A in some other 
way. Our data indicates that mutation of S342 to Alanine in human Aurora A results in an 
isoform displaying very similar activity to the wild type, which is, more importantly, not 
inhibited upon DNA damage (Krystyniak A. et al, 2006). Therefore we set out to 
investigate the importance of this site in Aurora A response to double-strand breaks 
introduced to DNA. We show that upon DNA damage PP1 is released from Aurora A and 
that this process is under control of phosphorylation status of S342. TPX2 is also partially 
separated from Aurora A upon etoposide treatment, a process that should impair the 
protection of T288 from dephosphorylation. On the other hand, the phosphorylation status 
of T288 remains unchanged, namely similar to that observed during transition through 
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mitosis, at least at early times after the induction of damage. Those results point to a far 
more complex regulation of Aurora A activity than it has been so far postulated and, for 
the first time, prove that S342 is indeed a site responsible for negative regulation of Aurora 
A.  
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Results and Discussion 
 
 
PP1 binding to Aurora A is abolished upon DNA damage 
 
Activated Aurora A is known to phosphorylate PP1 and therefore inhibit its activity in 
vitro as well as in vivo, although the evidence for direct phosphorylation is not available to 
date. On the other hand, PP1 was shown to dephosphorylate active Aurora A, and thereby 
abolish its activity in vitro. Considering our findings that Aurora A is inhibited in response 
to DNA damage, we set out to investigate the binding of PP1 to Aurora A in such 
conditions. We used etoposide, the topoisomerase II inhibitor, to create double-strand 
breaks in DNA after completion of its synthesis, namely 8 hours post-release from second 
thymidine block, when Aurora A level, activity as well as its PP1 binding is close to 
maximum. As shown previously (Krystyniak A. et al, 2006), etoposide-induced DNA 
damage leads to block of the cell cycle in G2, accumulation of Aurora A protein and 
inhibition of its kinase activity. In such conditions PP1 binding to Aurora A is highly 
decreased (Figure 1A). Treatment of cells with okadaic acid, a known inhibitor of both PP1 
and PP2A, resulted in partial, though reproducible, decrease in binding of Aurora to PP1. 
This indicates that binding of PP1 to Aurora A may partially depend on enzymatic activity 
of PP1 (Figure 1B).  
 
 
PP1 binding depends on S342 phosphorylation status 
 
Aurora A in known to posses two PP1-binding motifs, one that includes the catalytic lysine 
residue (K169VLF) and a second that is immediately adjacent to Serine 342 (K343VEF) 
(Katayama H. et al, 2001). The results above led us to formulate the hypothesis that 
phosphorylation of Aurora A at Serine 342 may alter binding of PP1 at the adjacent 
K343VEF motif, an event that may affect phosphorylation at the T-loop Threonine 288 as 
well as at other sites required for Aurora A activity (Littlepage L.E. et al, 2002). To test 
this hypothesis, we transfected Aurora A wild-type, as well as the non-phosphorylable 
S342A mutant or the “constitutively phosphorylated” S342D mutant (with Aspartic acid 
mimicking constitutive phosphorylation) into HEK-293T cells, between two thymidine 
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blocks. After release from the second Thymidine block and completion of DNA synthesis, 
cells were treated with etoposide to create double-strand breaks, and harvested at the time 
when they were supposed to have reached mitosis (6,5 hours for HEK-293T cells). 
Immunoprecipitation using polyclonal anti-Aurora A antibody (PAb-36) brought down 
both endogenous Aurora A together with recombinant wild-type or mutant kinase, as well 
as its interacting partner PP1.  
In mitotic cells (Figure 2B), the binding of PP1 to Aurora A appeared to be slightly lower 
in case of the S342A mutant (lane 3), compared to the wild-type (lane 2), and highly 
impaired in case of S342D mutant (lane 4) – the level of PP1 in this case is similar to that 
in the mock-transfected sample (lane 1). The small amount of PP1 co-immunoprecipitating 
with Aurora A in lane 1 is likely attributable to interaction with the endogenous kinase. 
Kinase-dead Aurora A mutant (mutation D145N), on the other hand, showed the greatest 
binding to PP1 (data not shown), supporting the hypothesis that Aurora A activity may 
play a role in controlling the extent of PP1 binding. Binding of wild type Aurora A to PP1 
was highly decreased upon DNA damage (compare lanes 2 with 6). In contrast, in case of 
S342A Aurora A there was only a slight decrease observed (compare lane 3 to 7).  
This data show that binding of PP1 to Aurora A depends on the phosphorylation status of 
Aurora A on Serine 342 and that, upon DNA damage, impaired phosphorylation at this site 
significantly prevents PP1 from dissociating from the complex.  
 
 
Wild-type and S342A mutant Aurora A, but not S342D mutant, can drive cells to mitosis 
 
The evidence presented above, together with previously published data (Krystyniak A. et 
al, 2006) that S342A Aurora A is resistant to DNA damage-induced inhibition and that 
introduction of this mutants into DNA-damaged cells causes even greater by-pass of the 
G2 arrest than wild-type, suggests that Serine 342 is a negative regulatory site for the 
activity of Aurora A. To further prove this hypothesis, transduction experiments in U2OS 
and HEK-293T cells using both AurA S342A and S342D mutants, were performed. Both 
FACS and immunofluorescence analysis of HEK-293T cells, providing a read-out for the 
cell cycle distribution and the presence of mitotic figures, respectively, showed that AurA 
wt and S342A mutant, but not S342D mutant, have the ability to push cells towards 
mitosis, despite the presence of DNA damage (Figure 3A and B). Western blot analysis, 
using as mitotic marker phosphorylated-H3, showed a signal only in extracts from cells 
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transduced with wild-type and S324A AurA (lanes 3 and 4, Figure 3C, respectively). No 
histone phosphorylation could be observed in control extracts from cell treated with 
etoposide and nocodazole (lane 1), as well as in extracts from cells transduced with S342D 
AurA (lane 5).  
 
 
TPX2 binding to Aurora A is decreases upon DNA damage 
 
TPX2 (Target Protein for Xenopus kinesin-like protein 2) is a microtubule-associated 
protein, which is required for induction of spindle assembly (Gruss O.J. et al, 2002). It has 
been shown that NH2 terminus of TPX2 binds to COOH-terminal catalytic domain of 
Aurora A, and targets it to the spindle apparatus (Kufer T.A. et al, 2002), namely spindle 
microtubules. Since we have previously shown that Aurora A is inhibited upon DNA 
damage, we set out to investigate whether there is any correlations between loss of kinase 
activity and disruption of the TPX2-Aurora A complex upon induction of double-strand 
breaks. To this end, we immunoprecipitated Aurora A from cells synchronized at the G1/S 
boarder (non-released from double Thymidine block), cells in M phase (10 hr from the 
release from the second Thymidine block) or cells treated with etoposide in the G2 phase 
of the cell cycle (8 hr) and harvested at the time corresponding to transition through M 
phase (10 hr from the release from the second Thymidine block) using polyclonal antibody 
PAb-36. The data showed that Aurora A protein co-immunoprecipitated with its partner 
TPX2. Aurora A level in G1/S cells was low (Figure 3B, lane 1), so non-surprisingly also 
its binding partner’s level was hardly detectable (Figure 3B, lane 5). Since TPX2 is known 
to be cell cycle regulated (Steward S. and Fang G., 2005), the low level of protein in G1/S 
cells was expected (Figure 3A, lane 1). On the contrary, the level of both proteins as well 
as their interaction increased and reach maximum in M phase (Figure 3B, lanes 2 and 6). 
Upon DNA damage, however, despite the level of both proteins was as high as in mitosis 
(Figure 3B, lane 3), interaction between them seemed to be significantly impaired, as 
indicated by the decrease in the co-immunoprecipitated TPX2 (Figure 3B, lane 7).  
Examination of the Aurora A and TPX2 distribution in the cells by immunofluorescence 
showed perfect co-localization in mitotic cells (Figure 3A, middle panel and Figure C, top 
panel). This is consistent with the known fact that TPX2 is involved in proper localization 
of Aurora A to the spindle poles and spindle microtubules (Kufer T.A. et al, 2002). 
Analysis of the time course co-localization of these two proteins revealed that at 8 hours 
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post-release Aurora A did not co-localize with TPX2, especially at centrosomes, 
suggesting that the interaction is tightly cell cycle regulated and restricted to the mitotic 
division. Late time points of mitosis showed partial loss of co-localization, with Aurora A 
being more abundant at centrosomes and TPX2 in the mitotic bridge.  
We have previously shown that, despite the presence of DNA damage, Aurora A is able to 
partially localize to the centrosomes, (Krystyniak A. et al, 2006). However, co-localization 
with TPX2 at centrosomes was not observed any longer under these conditions (Figure 3C, 
bottom panel and lower pictures of each panel of Figure 3A). TPX2 rather displayed 
diffused nuclear staining, which overlapped with the staining of Aurora A. This explains 
the residual interaction between the two proteins found in co-immunoprecipitation 
experiments, which seems at this point to be rather “physical” then “functional”.  
 
 
T288 phosphorylation status does not change upon DNA damage 
 
Similarly to a number of other kinases Aurora A activity is regulated by phosphorylation 
within the activation loop of the catalytic domain of the kinase, namely the conserved 
residue Threonine 288. Considering that phosphorylation at this residue results in a 
significant increase of Aurora A kinase activity, we decided to investigate the 
phosphorylation status of Aurora A’s Threonine 288 upon DNA damage. Western blot 
analysis using a specific antibody able to recognize phospho-Threonine 288, showed clear 
accumulation of phosphorylated Aurora A after treatment with okadaic acid (Figure 5A). 
This result was expected, given that inhibition of the two major phosphatase activities in 
the cell would tilt the balance toward phosphorylation, thus increasing the signal for 
phospho-Threonine 288 to a level higher than the “physiological” one observed in mitotic 
cells (Figure 5A, lanes 3 and 5 vs. lane 2). Surprisingly Aurora A remained phosphorylated 
at its activation loop after administration of etoposide (Figure 5B, lane 3), despite of the 
clear loss of kinase activity in these conditions (Krystyniak et al, 2006). 
Immunofluorescence examination of the cells showed strong staining with the antibody to 
phospho-Threonine 288 in cells analyzed at 10h post-release (Figure 5C, top panel), only 
in mitotic cells (as judged by chromosome condensation in DAPI labeled cells). In contrast 
cells treated with etoposide display quite strong, although diffused, staining in nearly all 
cells, without any signs of DNA condensation, or even centrosome separation (as a sign of 
Aurora A being active) (Figure 5C, bottom panel). This data goes in agreement with the 
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experiments done using crystal structures of Aurora A with or without its binding partner 
TPX2, which suggested that phosphorylation in the activation loop alone is not sufficient 
for enzyme activation (Eyers P.A. et al, 2005). 
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Materials and methods 
 
 
Expression vectors, chemicals, and antibodies 
 
Full-length Aurora A was obtained in PCR reaction as described previously (Krystyniak A. 
et al, 2006). The D145N, S342A and S342D mutants were generated using the 
QuickChange site-directed mutagenesis kit (Stratagene). Expression vectors for myc-
tagged forms of wild type and kinase-dead (D145N) Aurora a in pCS2 were kindly 
provided by P. Sassone-Corsi (Strasbourg, France). 
Recombinant proteins were generated by subcloning Aurora A ORF into pTXB3 vector 
(New England BioLabs) followed by expression of the intein-tagged fusion proteins in the 
BL21 Escherichia coli strain and purification using chitin beads.  
A polyclonal serum to Aurora A was generated as described (Krystyniak A. et al, 2006) 
and monoclonal antibody as described (reference!). A polyclonal antibody recognizing 
phosphorylated at T288 Aurora A was obtained from BioLegend. A monoclonal antibody 
to TPX2 was kindly provided by Dr Hans-Jürgen Heidebrecht. A monoclonal antibody to 
protein phosphatase 1 was obtained from Lab Force. 
The carrier peptide Pep-1 (Morris et al., 2001) was synthesized on a Milligen 9050 Plus 
automated peptide synthesizer (continuous flow) using chemical protocols based on Fmoc 
chemistry. The purity of the final compound was verified by reversed-phase analytical 
HPLC and the identity were assessed by correct mass spectral and amino acid analyses. 
 
 
Cell culture, synchronization, transfection and transduction 
 
HeLa and HEK-293T cells were maintained in DMEM (OmniLab) medium supplemented 
with 10% fetal calf serum (FCS, Life Technologies), penicillin (100U/ml) and 
streptomycin (100µl/ml). For synchronization experiments cells were treated with double 
thymidine block as described (Krystyniak A. et al, 2006). 
Transfections were done using Metafectene (Biontex) according to the manufacturer’s 
instructions.  
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Transductions were done using the carrier peptide Pep-1 according to the procedure 
described (Morris et al., 2001). Recombinant, purified proteins of Aurora A wild type and 
mutants S342A and S342D were used. 
 
 
Immunofluorescence 
 
Indirect immunofluorescence experiments were performed with cells grown on acid-
washed glass cover slips as described (Charrasse et al., 2000). Detection of AurA, P288-
AurA and TPX2 were performed with purified AurA-Pab36 polyclonal antibody (1/800), 
anti-T288-AurA polyclonal antibody (1/50) and monoclonal antibody to TPX2 (1/1), 
respectively. FITC-labelled (1/750), TRITC-labelled (1/50) or Texas Red-labelled (1/200) 
secondary antibodies were combined with DAPI (Molecular Probes). Cells were observed 
with a Leica DMRB microscope equipped with a 100W HBO lamp for fluorescence. High-
resolution pictures were taken with oil-immersion lenses (PL-FLUOTAR 40x-100x) and 
images were captured with a Leica DC 200 camera. Cells were viewed using Leica DC 
Viewer software and image merging was obtained using Adobe Photoshop 7.0. 
 
 
Western Blotting and Immunoprecipitation  
 
Cell extraction and detection of proteins by Western blot analysis was carried out as 
previously described (Charrasse et al., 2000). Immunoprecipitations were carried out for 3 
h at 4oC in Buffer A (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 
6 mM EGTA, 15 mM Na-pyrophosphate, 0.5 mM Na-orthovanadate, 1 mM benzamidine, 
0.1 mM phenylmethylsulfonil fluoride (PMSF), 1% Nonidet P-40) using 100, 200 or 500 
µg of total protein for CDK1, Chk2 or AurA, respectively. Proteins were immobilized on 
Protein A/G-Agarose beads (S. Cruz Biotech.) and washed in 3x 1 ml ice-cold Buffer A. 
AurA was routinely immunoprecipitated with purified AurA-Pab36 antibody and detected 
by Western blot with monoclonal antibody 35C1. 
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FACS and cell cycle analysis 
 
HEK-293T cells, synchronized by double thymidine block were treated with etoposide at 
4h post-release and half an hour later transduced with either wild type Aurora A or one of 
the S342 mutants (A or D). After 24h from release cells were trypsinized, washed with 
PBS and fixed with ice-cold ethanol for 12 hours in 40C. Fixed cells were treated for 30 
min with RNase A (100 µg/ml) (Sigma) at 370C, DNA was labeled with propidium iodide 
(PI) (20 µg/ml) (Sigma). Analysis was performed using FC500 cytometer (Beckman 
Coulter). 
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Figure legends 
 
 
Figure 1. Damage to DNA affects PP1 binding to Aurora A 
 
A. (Left panel) Detection of Aurora A and PP1 by Western blot analysis of whole-cell 
extracts (WCE) derived from double-thymidine synchronized HeLa cells; NR (non-
released) corresponds to cells in G1/S transition, 10h to mitotic cells, eto to cells treated 
with etoposide at 8h from the time of release from second thymidine block and harvested 
at 10h. (Right panel) Immunoprecipitation of 1 mg of the same WCE using anti-Aurora A 
polyclonal antibody followed by detection of precipitated Aurora A with its monoclonal 
antibody and detection of co-immunoprecipitated PP1 by Western blot.  
B. (Left panel) Detection of Aurora A and PP1 by Western blot of WCE derived from 
synchronized HeLa cells. 0 corresponds to cells in G1/S, 10h to mitotic cells. Cells were 
treated with etoposide as described above and with okadaic acid at 7,5h from the release 
from the second thymidine treatment. (Right panel) Immunoprecipitation of 1 mg of the 
same WCE and detection by Western blot as described above.  
 
 
Figure 2. Phosphorylation status of serine 342 plays a role in PP1 binding to Aurora A 
upon DNA damage.  
 
A. 293T cells were synchronized by double-thymidine block and transfected with various 
Aurora A constructs in between the two blocks. 1 mg of DNA was introduced to the cells 
of either pcDNA3.1 vector (mock), Aurora A wild type (AurAwt), Aurora A point-mutated 
at D145->N (AurAkd), Aurora A point-mutated at S342->A (AurAS342A), Aurora A 
point-mutated at S342->D (AurAS342D) or Aurora A point-mutated at S51->D 
(AurAS51D). Cells were either collected at 8h (time corresponding to mitosis in 293T 
cells) (left) or treated with etoposide at 4h from the second release from the thymidine and 
harvested at 8h (right). Western blot analysis of 10 µg of WCE followed by detection of 
Aurora A, both endogenous and recombinant, and PP1.  
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B. Immunoprecipitation of 1 mg of above described WCE with anti-Aurora A polyclonal 
antibody followed by detection of Aurora A and PP1 by Western blot.  
 
 
Figure 3. Transduction of wt-AurA in etoposide-damaged cells promotes entry into 
mitosis. 
 
A. Double thymidine block-released HEK-293T cells were treated left untreated (NT), or 
treated with etoposide at 4 h (eto). Cells treated with etoposide as in (eto) were transduced 
at 4,5 h post-release with wt-AurA (AurAwt, eto), or AurA S342A (AurA342A, eto) or 
AurA S342D (AurA342D, eto). Cells were analyzed at 8 h by immunofluorescence using 
anti-AurA polyclonal antibody.  
B. Double-thymidine synchronized HEK-293T cells were treated with etoposide and 
transduced as in panel A. Cells were harvested at 24h after release from the second 
thymidine block and subjected to FACS analysis. 
C. Double thymidine block-released U2-OS cells were treated with etoposide at 8 h and 
nocodazole at 9h or with nocodazole alone. Cells treated with etoposide and nocodazole 
were transduced at 10 h post-release with wt-AurA, or AurA S342A or AurA S342D. Cells 
were harvested after 24 hours post-release and protein extracts analyzed by Western blot, 
using anti-H3 antibody for detection of mitotic cells. PP1 detection serves as loading 
control.  
 
 
Figure 4. Binding of TPX2 to Aurora A is impaired upon DNA damage 
 
A. (Left panel) Detection of Aurora A and TPX2 by Western blot analysis of whole-cell 
extracts (WCE) derived from double-thymidine synchronized HeLa cells; NR (non-
released) corresponds to cells in G1/S transition, 10h to mitotic cells, eto to cells treated 
with etoposide at 8h and OA to cells treated with okadaic acid at 7,5h from the time of 
release from second thymidine block and harvested at 10h. (Right panel) 
Immunoprecipitation of 1 mg of the same WCE using anti-Aurora A polyclonal antibody 
followed by detection of precipitated Aurora A with its monoclonal antibody and detection 
of co-immunoprecipitated TPX2 by Western blot.  
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B. Immunofluorescence analysis of time-course of HeLa cells, synchronized by double 
thymidine block. Details of the procedure in Materials and methods 
C. Immunofluorescence analysis of mitotic HeLa cells (control) and cells treated with 
etoposide at 8h from the release from the second thymidine block and analyzed at 10h 
(time corresponding to mitosis). Magnification of single cell showed.  
 
 
Figure 5. Phosphorylation status of T288 is not affected upon DNA damage 
 
A. HeLa cells were synchronized by double-thymidine block and treated with or without 
okadaic acid at 7,5h from the time of the second release. Cells were harvested at indicated 
time points and the total level of Aurora A protein as well as the level of phosphorylated at 
T288 fraction was analyzed by Western blot, using polyclonal anti-Aurora A antibody and 
specific antibody recognizing Aurora A phosphorylated at T288. Beta-tubulin serves as a 
loading control.  
B. Detection of Aurora A total protein and Aurora A fraction phosphorylated at T288 by 
Western blot analysis of whole-cell extracts (WCE) derived from double-thymidine 
synchronized HeLa cells; NR (non-released) corresponds to cells in G1/S transition, 10h to 
mitotic cells, eto to cells treated with etoposide at 8h and OA to cells treated with okadaic 
acid at 7,5h from the time of release from second thymidine block and harvested at 10h. 
Beta-tubulin serves as a loading control. 
C. Immunofluorescence analysis of Aurora A phosphorylated at position T288. Mitotic 
cells at the top panel, cells treated with etoposide at the bottom panel.  
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1. LOOKING FOR AURORA A INTERACTION PARTNERS – p62 
(project with collaboration with Dr Torsten Kleffmann and Functional Genomics Center, 
University of Zürich) 
 
2. RNA INTERFERENCE IN CANCER CELL LINES OVEREXPRESSING 
AURORA A 
(teamwork project with Christiane König) 
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1. LOOKING FOR AURORA A INTERACTION PARTNERS – p62 
(project with collaboration with Dr Torsten Kleffmann and Functional Genomics Center, 
University of Zürich) 
 
The goal of the study was to identify new interaction partners of Aurora A with potential 
distinction between normal and DNA damage conditions. 
 
 
1.1. Introduction 
 
Ubiquitin is a small polypeptide of 76 amino acids that can be covalently attached to other 
proteins through an isopeptide bond. Ubiquitination occurs through sequential steps 
catalyzed by activating (E1), conjugating (E2) and ligating (E3) enzymes. 
Monoubiquitination plays a role as an endocytosis signal and as a signal for polymerase 
switch in case of monoubiquitination of PCNA, whereas polyubiquitin chains target 
substrates for degradation by the proteasome. Using energy derived from ATP hydrolysis 
the 26S proteasome unfolds the substrate polypeptide chain and translocates it into an 
interior chamber where the substrate is hydrolyzed to produce small peptides. Ubiquitin is 
not degraded there since it is released from the substrate by deubiquitinating enzymes 
(Figure 2).  
 
 
 
 
 
 
Figure 2. Components and mechanisms 
in the ubiquitin/proteasome pathway 
(from Pickart C.M., 2004), details in the 
text 
 
 
 
E1 activates ubiquitin by using ATP to synthesize ubiquitin C-terminal adenylate, which 
then serves as an enzyme bound substrate for the formation of an E1- ubiquitin thiol ester. 
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The activated ubiquitin molecule is passed to a cysteine residue of the E2 component and 
from there, in an E3-dependent manner, to the substrate, where the isopeptide bond is 
formed between the activated C-terminal glycine of ubiquitin and an ε-amino group of a 
lysine in the substrate (Figure 3). 
 
 
 
Figure 3. The ubiquitin 
conjugation cascade. (from Pickart 
C.M., 2004) 
 
 
 
Following the linkage of the first ubiquitin, additional molecules of ubiquitin are attached 
to the previously conjugated moiety to form branched polyubiquitin chains employing 
lysine linkage K29, K48, or K63 (Pickart C.M., 2001). It has been postulated that the fate 
of a substrate depends on the length of the chain as well as the lysine linkage (K29, K48, or 
K63) involved in forming the chain. Proteins possessing K48 chains target proteins to the 
proteasome, whereas the ones with K63 have been shown to have other role than 
proteasome targeting. Ubiquitin itself is known to be modified at all seven lysine residues 
(K6, K11, K27, K33, K29, K48, and K63) adding additional potential diversity to 
polyubiquitin chains (Peng J., at al, 2003). 
 
 
1.2. Materials and methods 
 
1.2.1. Immunoprecipitation and mass spectroscopy 
 
HeLa cells were treated with double thymidine block as described (Krystyniak A. et al, 
2006). After 8h from the second thymidine release, cells were treated in the presence or 
absence of etoposide for subsequent 2 hours, then harvested. Immunoprecipitations of 
10mg of total cell extract were carried out as described below, over night at 4oC, with 
constant rotation, using 20 µl of anti-Aurora A polyclonal antibody and 50 µl of Protein A 
Sepharose beads (S. Cruz Biotech.). Immunoprecipitates were washed 3x 1 ml ice-cold 
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Buffer A (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM 
EGTA, 15 mM Na-pyrophosphate, 0.5 mM Na-orthovanadate, 1 mM benzamidine, 0.1 
mM phenylmethylsulfonil fluoride (PMSF), 1% Nonidet P-40) and boiled (5 min at 950C) 
in SDS sample buffer, then loaded on the 10% polyacrylamide gel. The gel was stained 
with Coomasie Brilliant Blue to visualize protein bands. Each lane, corresponding to one 
immunoprecipitation was cut into 8 pieces and each piece was then prepared for MS 
separately. Gel pieces were digested with trypsin (Roche sequencing grade) according to a 
described protocol (Shevchenko A., et al, 1996). After overnight incubation the 
supernatant was removed and the remaining peptides were extracted three times with 80% 
acetonitrile / 10% formic acid. Samples were dried in a vacuum centrifuge and then 
subjected to MALDI-ToF-MS analysis.  
The obtained peptide mass lists were searched against human protein data base 
ProteinPhophet.  
 
 
1.2.2. Co-expression and co-immunoprecipitation 
 
HEK-293T cells were maintained in DMEM (OmniLab) medium supplemented with 10% 
fetal calf serum (FCS, Life Technologies), penicillin (100U/ml) and streptomycin 
(100µl/ml). 
Transfections, using myc-tagged Aurora A, flag-tagged p62 and empty pcDNA3 vector as 
mock control, were done using Metafectene (Biontex) according to the manufacturer’s 
instructions. Cells were harvested for protein level analysis and IP experiment after 24h 
post transfection. 
Cell extraction and detection of proteins by Western blot analysis was carried out as 
previously described (Charrasse et al., 2000). Immunoprecipitations were carried out for 
3h at 4oC in Buffer A (described above) using 1mg of total protein. Proteins were 
immobilized on Protein A Sepharose beads (S. Cruz Biotech.) and washed in 3x 1 ml ice-
cold Buffer A. 5 µl of polyclonal AurA-Pab36 antibody was used for each 
immunoprecipitation whereas detection by Western blot was performed with monoclonal 
antibody AurA-35C1 and anti-Flag antibody for p62. 
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1.3. Results 
 
1.3.1. Mass spectroscopy 
 
Combined and selected results of the mass spec analysis are presented in Table 1. Protein 
Q13446 was identified as Sequestosome-1/p62 (known also as: phosphotyrosine-
independent ligand for the Lck SH2 domain of 62 kDa, ubiquitin-binding protein p62, 
EBI3-associated protein of 60 kDa, p60, EBIAP). The signal for p62 was found in both 
non-treated and eto-treated samples with protein probability (score) of 0.62 and 1.0, 
respectively. The sequence coverage was 5,9% in the sample of non-treated cells and 
11,6% in the sample of cells treated with etoposide, which in the latter case corresponded 
to 3 different peptides.  
 
 
1.3.2. Co-immunoprecipitation 
 
In order to confirm the results from mass-spec analysis, showing that Aurora A interacts 
with p62, we co-transfect exponentially growing HEK-293T cells with 1µg (for 10 cm 
dish) for each of the two construct, namely myc-AurA and flag-p62. Western blot analysis 
confirmed the presence of both transfected proteins (lane 2 in Figure 5A and lane 3 in 
Figure 5B). The corresponding bands were not present in mock-transfected samples (lane 1 
in 5A and lane 2 in 5B), confirming the specificity of the detection.  
Immunoprecipitation was carried out using polyclonal AurA-Pab36 antibody as described 
in Materials and Methods. Western blot analysis of immunoprecipitated proteins using the 
anti-flag antibody detected a band of size corresponding to p62 (lane 4, Figure 5A). In 
order to further confirm the specificity of this interaction, the membrane was stripped and 
re-probed with monoclonal AurA-35C1 antibody (Figure 5A). The latter recognized 
ectopically expressed Aurora A both in total cell extract and in immunoprecipitated 
complexes. The lower band, visible only upon immunoprecipitation (lanes 4 and 5, Figure 
5B) represents endogenous Aurora A. Due to its low level in asynchronously growing 
cells, this band is not detectable in Western blot analysis of total cell extracts. 
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Figure 5. Aurora A interacts with p62. A. Detection of overexpressed p62 in WB (left part) and in co-
immunoprecipitation (right panel). B. Detection of Aurora A (with monoclonal antibody) in WB (left part) 
and in immunoprecipitation (right part). First line is a recombinant purified kinase dead Aurora A, expressed 
and purified form E.coli, serving as a size and expression control.  
 
 
 
1.4. Outlook  
 
We were able to show the interaction between Aurora A and p62 by means of mass 
spectroscopy analysis and direct immunoprecipitation. 
 
p62 is a cellular protein cloned as a co-interacting protein of the atypical protein kinase Cζ 
(aPKCζ) (Puls A. et al, 1997). p62 was shown to bind to the SH2 domain of p56lck in a 
phosphotyrosine-independent manner (Park I. et al, 1995). The ability of p62 to bind 
ubiquitin in a non-covalent fashion was mapped to amino acids 386–434 in the C-terminus 
of the protein, a region that shows homology with other proteins possessing an ubiquitin-
associated (UBA) domain (Vadlamudi R.K., et al, 1996). Further studies have revealed that 
p62 has affinity for multi-Ub chains and may serve as a receptor to bind and store 
ubiquitinated proteins (Shin J. 1998). p62 contains several structural motifs, like acidic 
interaction domain (AID/ORCA/PC/PB1) that binds the aPKC, a ZZ finger, a binding site 
for the RING finger protein TRAF6, two PEST sequences, and, mentioned above, an UBA 
domain (scheme shown at Figure 1). The presence of these motifs suggests that p62 may 
participate in the formation of multimeric signal complexes.  
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Figure 1. A schematic diagram showing the domain organization of the p62 protein. (after Geetha T. 
and Wooten M.W., 2002) 
 
 
Recent studies confirmed that the UBA domain of p62 binds preferentially K63-
polyubiqiutinated substrates and that it interacts with the proteasome (Seibenhener M.L., et 
al. 2004). It was shown that depletion of p62 results in inhibition of ubiquitin proteasome-
mediated degradation and accumulation of ubiquitinated proteins, supporting the 
hypothesis of p62 as critical ubiquitin chain-targeting factor that shuttles substrates for 
proteasomal degradation.  
Moreover, p62 is known to function as a scaffold in a range of signaling pathways 
associated with cell stress, survival and inflammation, and also controls transcriptional 
activation and protein recruitment to endosomes. The most well-described and extensively 
studied function of p62 is its role as a scaffold for selective activation of transcription 
factor NF-κB (Geetha T. and Wooten M.W., 2002).  
 
Aurora A degradation is known to be dependent on the ubiquitin ligase activity of the 
APC/cyclosome, specifically on Cdh1. The detailed mechanism of regulation of this 
process remains to be explored. Our data, showing the interaction between Aurora A and 
p62, point to the possible involvement of p62 in the mechanism of shuttling poly-
ubiquitinated Aurora A to the proteasome. Functional assays using siRNA technology will 
be now needed to support the relevance of Aurora A – p62 interaction at mitosis and to test 
the hypothesis on a possible role of p62 in the process of Aurora A degradation.  
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Table1. Mass spectroscopy analysis of Aurora A interacting proteins.  
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2. RNA INTERFERENCE IN CANCER CELL LINES 
OVEREXPRESSING AURORA A 
(teamwork project with Christiane König) 
 
 
2.1. Introduction and aim of study 
 
The hallmark of cancers is genetic instability, which can be caused by specific gene 
mutations and/or acquired aneuploidy. One of the important players in maintaining 
genomic stability are centrosomes, the organelles establishing bipolar spindles during cell 
division and accurate segregation of chromosomes during cell division. Defect in 
centrosome number, organization and function may lead to ch mosome amplification or 
loss and further to aneuploidy. Aurora A kinase plays an important role in chromosome 
segregation and centrosome functions. The gene encoding Aurora A is frequently 
amplified and overexpressed in various kinds of human cancer, including breast, 
colorectal, bladder, thyroid and others (Bischoff J.R., at al, 1998), (Royce M.E., et al, 
2003), (Kamada K., et al, 2004), (Ulisse S., at al, 2006). Moreover, ectopic expression of 
Aurora A in mouse NIH3T3 cells and Rat1 fibroblasts causes centrosome amplification 
and transformation (Zhou H., et al, 1998). Those facts suggest that Aurora A may play a 
central role in the development of cancer.  
We were able to show that treatment of cells with etoposide, an inhibitor of topoisomerase 
II that leads to the formation of double-strand breaks in DNA, caused inactivation of 
Aurora A, resulting in cell cycle arrest at the G2 phase. We could also show that such 
block was bypassed upon over-expression of wild type Aurora A (Krystyniak A., et el., 
2006).  
 
Drowning from the observations described above, we decided to test the hypothesis that 
elevated level of Aurora A in cancer cell lines may lead to higher resistance to etoposide. 
We postulated that in this case, down regulation of Aurora A by RNA interference would 
restore the sensitivity to etoposide. In a recently published study it was shown that down-
regulation of Aurora A by siRNA in human pancreatic cancer cells enhanced the 
sensitivity to taxane and suppress tumor growth (Hata T., 2005).  
 
ro
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2.2. Materials and methods  
 
 
2.2.1. Cell lines, media and reagents 
 
The human cervix carcinoma cell line HeLa and the human colorectal adenocarcinoma cell 
line CACO were maintained in DMEM (OmniLab) medium supplemented with 10% fetal 
calf serum (FCS, Life Technologies), penicillin (100U/ml) and streptomycin (100µl/ml). 
The human rectum adenocarcinoma cell line SW837 was maintained in the same medium 
with the additional 1% L-Glutamine. The human hereditary spherocytosis cell lines MT1 
and TK6 were maintained in RPMI medium (Gibco) supplemented with 10% FCS and 
antibiotics. In order to perform shRNA experiments (see below) cell lines were tested for 
sensitivity to puromycin. 
In order to obtain M-phase synchronization, cells were treated with Nocodazole 
(200ng/ml) for 15 hours.  
 
 
2.2.2. MTT assay 
 
Cells were seeded in 96-well plates in the concentration of about 5000 cells per well in 
100µl of medium. The day after cells were treated with various concentrations of 
etoposide, ranging from 0,1µM up to 50µM, for 72 hours. In order to check the viability to 
each well 20µl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
solution (5µg/ml in PBS) was added and plates were incubated for about 4 hours in 370C. 
Then 100µl/well of lysis buffer (25ml ddH2O, 25ml NN-dimethylformamid, 10g SDS, pH 
4.7) was given and the plates were further incubated in 370C for overnight. Light 
absorption was read in ELISA reader at 570nm. 
 
 
2.2.3. siRNA 
 
Short double-strand RNA oligonucleotides (siRNA) (Ambion) for interference in the 
expression of Aurora A RNA were: 5’-UUCUUCCCAGCGC UUCCUtt-3’ (sense) and A
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5’-AGGAAUGCGCUGGGAAGAAtt-3’ (antisense). The annealed oligonucleotides were 
dissolved in RNA-free water to obtain 100 µM stock solution. In vitro transfections were 
carried out in 6-well plates, using Oligofectamine reagent (Invitrogen) according to the 
manufacturer’s instructions. Cells were harvested 24, 48, 72 and 96 hours upon 
transfection and the expression of Aurora A was controlled by Western blot analysis.  
 
 
2.2.4 shRNA 
 
The following hairpin oligonucleotides: AurA shRNA top: 5’-
GATCCCCGTTCTTCCCAGCGCATTCCTTTCAAGAGAAGGAATGCGCTGGGAAG
AATTTTTA-3’ and AurA shRNA bottom: 5’-
AGCTTAAAAATTCTTCCCAGCGCATTCCTTCTCTTGAAAGGAATGCGCTGGGAA
GAACGGG-3’, containing restriction sites for BglII and HindIII, were diluted in RNA-
free water to final concentration 100 µM and annealed. Double-stranded hairpin 
oligonucleotides were digested and, after gel purification, cloned into BglII-HindIII 
restricted pSUPER vector (OligoEngine), which carries resistance to puromycin.  
 
 
 
2.3. Results and comments 
 
2.3.1. Aurora A is over-expressed in several cancer cell lines
 
Several cancer cell lines were tested for overexpression of Aurora A. Among them were 
the spleen cell lines TK6 and the mismatch-resistant variant MT1 (human hereditary 
spherocytosis), CACO (human colorectal adenocarcinoma) and SW837 (human rectum 
adenocarcinoma).  
All cell lines showed elevated expression of Aurora A as evidenced by Western blot 
analysis. The amount of Aurora A was further increased upon synchronization of the cells 
in M phase with Nocodazole (Figure 1).  
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Figure 1. Level of Aurora A protein in different cell lines. Low and hig evel of Aurora A expression in 
exponentially growing and Nocodazole-treated HeLa cells, respectively, were used as control 
 
 
2.3.2. Cells expressing higher amounts of Aurora A are more resistant to etoposide 
 
In order to assess whether overexpression of Aurora A in uences the sensitivity to 
etoposide we performed MTT assays on HeLa cells (as control) and on SW837 cells. The 
data show that SW837 cells, overexpressing Aurora A, display IC50 for etoposide that is 
about 10 times higher than HeLa cells (at 72h of etoposide treatment) (Figure 2).  
 
 
h l
fl
 
 
Figure 2. SW837 are about 10 times more resistant to etoposide. The cells were seeded in two different 
amount, namely 6000 and 3000 cells per well (SW837) and 1600 and 800 c ls per well (HeLa). el
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Although the difference between HeLa and SW837 cells are certainly not limited to the 
overexpression of Aurora A, these data suggest that the latter might be an important factor 
in the observed 10-fold increased resistance of SW837 to etoposide. 
 
 
2.3.3. siRNA approach to down-regulate AurA level in cancer cell lines 
 
In order to test the quality of the small interference RNA to Aurora A that we designed we 
first tested its effect in HeLa cells, which are known to be easily transfectable with RNA. 
Two concentrations of siRNA were used to check the selective down-regulation of Aurora 
A and eventual side effects (mortality of cells). Western blot analysis using specific 
antibodies revealed down-regulation of Aurora A expression to an extent of about 80% at 
48h post-treatment, even with the lower concentration of oligonucleotide employed (50 
nM), However, in order to obtain prolonged down-regulation of Aurora A expression to 
extent that is compatible with the duration of cell survival assays (MTT), higher am
oligo was necessary (100 nM) (Figure 3).  
 
 si
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Figure 3. Down-regulation of Aurora A by siRNA in HeLa cells. The concentration of the 
Oligonucleotides is expressed in nanomolarity. 
 
 
The same strategy was employed for SW837 cells. In this case, however, no down-
regulation of Aurora A was observed due to the low transfection efficiency of these cells, 
as observed in control transfection experiments where an FITC labeled double-stranded 
oligonucleotide or the green fluorescent protein (GFP) vector were used. Several other 
methods of transfection were tested, such as Lipofectamine 2000 (Invitrogen), Interferin 
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(PolyPlus Transfections) and electroporation using siPORT buffer (Ambion) and XCell 
electroporator (BioRad) at various conditions of pulse length (75-200µs) and/or strength 
(200-400V). None of them, however, gave satisfactory result. 
 
 
2.3.4. shRNA approach to down-regulate AurA level in cancer cell lines 
 
Taking into account the obstacles mentioned in paragraph 2.3.3 we decided to down-
regulate Aurora A expression using an shRNA approach followed by cloning of shRNA-
carrying cells and antibiotic selection. This approach seems to posses several advantages: 
(1) even low transfection efficiency would be enough to select single, transfected with 
shRNA, cells; (2) the level of Aurora A down-regulation in cells derived from a single 
clone will be identical; (3) different clones, may display different down-regulation level, 
which would enable us to closer examine the effect of etoposide and sensitivity to it in 
regard to amount of Aurora A protein present. 
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